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ABSTRACT
Increased interleukin-11 and stress genes
in human endothelial and 
human bronchial epithelial cell lines
by silver nanoparticles
Jiyoung Jang
Graduate Program for Nanomedical Science
The Graduate School Yonsei University
(Directed by Professor In-Hong Choi)
The ultrafine particle size of nanomaterials is limited to approximately 
100 nm, and such a small size has allowed nanomaterials to be used in a 
variety of ways. Therefore, engineered nanoparticles are being used in 
various industries, including ceramics, polymers, smart textiles, 
pharmaceutical products, cosmetics, biomedicine, electronics, paints,
xii
chemicals, food, and environmental analysis. Metal nanoparticles that 
contain gold, silver, iron, zinc, and metal oxides are widely used for their 
large surface area to volume ratios and their unique physicochemical 
properties. In particular, silver NPs are in especially wide use in the 
medical field, where they are used in diagnosis and treatment and 
incorporated into medical devices and pharmaceuticals. Interestingly, 
however, silver NPs have been identified as a cause toxicity in the human 
body. Because of their small size, NPs that enter the human body can easily 
penetrate biological barriers and can be circulated throughout the entire 
body, ultimately reaching the vascular endothelium. 
With this in mind, the present study aimed to identify various cell 
responses by distinguishing between endothelial and epithelial cells and 
exposing them to silver nanoparticles (NPs). The study also worked to 
identify the progression of cell apoptosis that occurs as a result of
intracellular oxidative stress caused by silver NPs and to determine which
genes are being stimulated in order to cause such changes. We also 
assessed several gene expression levels that increased significantly in the 
microarray assay.
We evaluated the cytotoxic effects of silver NPs both endothelial and 
epithelial cells. Although the LD50 of each cell line was estimated 
differently, we were able to prove the toxicity of silver NPs. Meanwhile, for
100 nm silver NPs, cell death was not observed in the high concentration 
group. We verified through microarray that 5 nm silver NPs affect the 
xiii
variation of gene expression in cells, and a noticeable increase in the 
expression of interleukin (IL)-8 and IL-11 genes in early time was also 
verified. This study found that the variation in oxidative stress-related 
genes in early time, and among them the variation of metallothionein (MT), 
heme oxygenase 1 (HO-1), and heat shock 70kDa protein (HSP70) 
expression, was noticeable. This study proves that HSP70, HO-1, and MT 
are sufficient as biomarkers of reactive oxygen species (ROS) and that the
oxidative stress effect is greater as the size of NPs is smaller assuming
that there is no variation in ROS related gene expression in 100 nm silver 
NPs. The microarray used in this study can analyze up to 24,838 RefSeq 
(Entrez) genes. Based on this analysis, genes undergoing intracellular 
change after exposure to silver NPs were classified into five categories: 
cell death, cell survival, inflammation, apoptosis, and ROS. As a result, 
there was considerable variation in genes related to cell death and 
apoptosis, and the expression of genes related to cell survival was also not 
negligible. Meanwhile, the number of genes related to inflammation was 
relatively small. Moreover, what is especially worth paying attention to is 
the increased IL-11 gene expression, which has not been much discussed 
in previous studies. In this study, the IL-11 gene expression particularly 
increased following the exposure of endothelial and epithelial cells to 5 nm 
silver nanoparticles. This study therefore verifies that IL-11 expression 
commonly increases in cells under the influence of silver NPs. 
In conclusion, this study finds that intracellular genes specifically 
xiv
respond to exposure to silver NPs and that the expression of IL-11 among 
cytokines is noticeable. It also finds that the toxic effect is affected by the 
size of NPs. However, this study verifies only that IL-11 expression 
increased, and thus further study would be required to elaborate on the
various roles played by IL-11.1
                                        
Key words: silver, nanoparticle, endothelial cell, epithelial cell, interleukin-11
１1. Introduction
The ultrafine particle size of nanomaterials is limited to approximately 
100 nm, and such a small size has allowed nanomaterials to be used in a 
variety of ways. In contrast, fine particles have sizes that range from 100 
and 2,500 nm (1). Advancements in nanotechnology have led to tiny-scale 
substances having a significant impact on our lives. Today, nanotechnology 
is one of the leading scientific fields, combining the fields of physics, 
chemistry, biology, medicine, pharmaceutical science, informatics, and 
engineering to establish another major scientific field (2). Nanotechnology 
represents a dynamic emerging field, with 50,000 or so articles being 
published each year, and according to the European Patent Office more than 
2,500 patents have been filed in recent times (3). 
Owing to their excellent usability, engineered nanoparticles are being 
used in various industries, including ceramics, polymers, smart textiles, 
pharmaceutical products, cosmetics, biomedicine, electronics, paints, 
chemicals, food, and environmental analysis (4). In particular, metal 
nanoparticles that contain gold, silver, iron, zinc, and metal oxides are 
widely used for their large surface area to volume ratio and their unique 
physicochemical properties, including a high electrical and thermal 
conductivity and optical, magnetic, and catalytic activity (5, 6). According 
to a recent report, about 29% of consumer products in the consumer 
２products inventory (including water, lotion, oil, and car lubricants) contain 
nanomaterials suspended in a variety of fluids. The second largest group in 
this category comprises solid products with surface-bound nanoparticles
such as curling irons, flat irons, and textiles (7). Among them, the 
antimicrobial and antifungal effects of silver nanoparticles (NPs) have led 
to the rapid develop of consumer products applications, and the number of 
worldwide products based on silver NPs has reached over 313 (5). Silver 
NPs are in especially wide use in the medical field, where they are used in 
diagnosis and treatment and incorporated into medical devices and 
pharmaceuticals. Moreover, silver NPs are widely used for to coat medical 
tools as well as to sterilize of materials in hospitals (2). In addition, in 
many products different nanomaterials are combined with others. Silver and 
titanium dioxide are the nanomaterial components most likely to be 
combined with other nanomaterials in consumer products, with 35 and 30 
product combinations, respectively. Silver and titanium dioxide were paired 
with each other in 10 products (mostly cosmetics and electronics); titanium 
dioxide and zinc oxide were paired in 10 products (mostly sunscreens, 
cosmetics, and paints). The European Commission’s Cosmetics Regulation 
has permitted the use of nanoscale titanium dioxide in sunscreens, but not 
zinc oxide (7).
However, an interesting point is that silver NPs have been identified as a 
cause of toxicity in the human body; they are therefore dual-natured, with 
both positive and negative aspects. Consequently, many researchers are 
３conducting toxicity evaluations and risk assessments of NPs. 
All NPs are taken up by mammalian cells by such mechanisms as 
pinocytosis, endocytosis dependent on caveolae and lipid raft composition, 
clathrin-dependent endocytosis, and phagocytosis (8), and silver NPs are 
no exception in this respect. As some studies have shown, normal human 
lung fibroblasts (IMR-90) and human glioblastoma (U251) take up silver 
NPs by clathrin-dependent endocytosis and macropinocytosis. In the case 
of silver NPs (6-20 nm), they were usually present inside cells after a 2 h 
treatment; uptake was linear during 2 h - 48 h exposure and was the result 
of a balance between exo- and endocytosis (8).
In one study, toxicoproteomic evaluation following exposure to silver NPs 
showed an altered pattern of protein expression (9), indicating that silver 
NP toxicity can cause pathological changes in the human body. A recent 
study reported that the surface charge of silver NPs was associated with 
silver NP toxicity (10). The degree of human toxicity can vary depending 
on the size of the NPs to which the body is exposed. When macrophages 
were exposed to 5 nm and 100 nm silver NPs, the group exposed to 5 nm 
silver NPs showed an increase in interleukin-8 expression even early in 
the exposure and at low concentrations where cell death did not occur. This 
indicated that smaller NPs can have an inflammatory effect on the
intracellular immune system (11). Silver NPs also stimulate cytotoxic 
mechanisms, producing an indirect effect on the release of lactate from 
hepatoma cells. One study reported that reactive oxygen species (ROS) 
４were generated through the secondary influence of NPs, not through their 
direct influence, which resulted in proportionate decreases in lactate 
release (12). According to another study, exposing rat liver epithelial cells 
to silver NPs resulted in a significant increase in intracellular ROS 
concentration and a decrease in glutathione (GSH) levels, but it was 
unclear as to whether this was due to GSH directly binding with silver NPs
or to GSH synthesis being inhibited by enzymes. A dose-dependent 
decrease in mitochondrial membrane potential was also found, and cell 
viability was also noted to be associated with NP exposure, but whether 
this was attributable to the influence of NPs or Ag+ ions was not clearly 
identified (13). Another study examined the cytotoxic effects of silver NPs 
on human liver cells. The study results showed that silver NPs caused 
damage to cellular components by inducing ROS generation and reducing 
GSH levels as well as by causing DNA breakage, lipid peroxidation, and 
protein carbonylation. Based on these findings, the study concluded that 
silver NPs are involved in the GSH depletion mechanism and that their 
presence induces the mitochondria-dependent apoptotic pathway (14). In a 
recent study, human umbilical vein endothelial cells (HUVECs) were 
treated with 6 types of NPs. The most noticeable aspect of that study is
that the endothelial cells were exposed to NPs by applying a flow system. 
In most in vitro experiments, tests were performed under static conditions, 
whereas this study exposed the cells to NPs under fluid conditions. This 
experimental setting was closest to the actual situation of NPs being 
５exposed to human tissues as they move through the circulatory system in 
the human body, and the results show that silver NPs were most toxic: 
silver NPs not only caused inflammation and activation of an IL-8 
dependent pathway but also induced pro-apoptotic signals that led to cell 
apoptosis. Moreover, endothelial cells were more sensitive to silver NPs 
under flow conditions. The authors of that paper suggest that a 
physiologically-related in vitro model was needed in order to understand
the hazards of NPs (15). In addition to these studies, a few other in vitro
studies have also reported that increasing the exposure of macrophages 
and human peripheral blood mononuclear cells to silver NPs resulted in the 
release of various cytokines (16, 17, 18). 
Many nanotoxicology studies have focused on the in vitro cell culture 
system. However, the data from these studies could be misleading, and it is 
difficult to view the results as a whole of organism response. Animal 
studies (in vivo models) are very helpful for understanding the chemical 
properties of nanomaterials and the response relationship between 
organisms, including humans. Using an in vivo system can provide some 
basic information on the pathway that NPs use to move through the body 
after exposure (19). In animal studies, silver NPs are usually applied in a 
suspended state, allowing Ag+ ions to be released from the suspension. 
However, it is still unclear whether the signs of toxicity that result from 
exposure to silver NPs is due to the small size of the NPs, the silver ions 
generated in the suspended state, or a combination of both (20). In a 2010 
６study of toxicity and inflammation response following silver NP exposure in 
mice, the authors repeated oral administration of silver NPs of different 
sizes (22, 42, 71, 323 nm) to mice for 14 days. According to the results, 
silver NPs of different sizes were distributed in various tissues, with 
small-sized silver NPs appearing even in the brain, lungs, liver, kidney, and 
testes, whereas such a pattern was not found in the group treated with 
large-sized 323 nm silver NPs. In addition, when varying concentrations of 
42 nm silver NPs were orally administered repeatedly for 28 days, the 
groups treated with higher concentrations showed an increase in markers 
indicative of liver damage. Based on these results, the authors concluded
that silver NPs are capable of causing hepatotoxicity, though
histopathological changes in the liver were not found. On the other hand, 
oral administration resulted in distinct increases in inflammatory responses, 
including increased cytokine production and increased B cell distribution
(21). However, a subsequent study that contradicted these findings was 
also published. In that study, observations were made after 28 days of 
exposure to non-coated silver NPs, polyvinylpyrrolidone (PVP)-coated 
silver NPs, and Ag ions. Contrary to the previous study, the results showed 
no liver damage, while blood, lymphocyte proliferation, and cytokine 
release showed little difference against the control, which indicated no 
hepatotoxicity or immunotoxicity from silver NP exposure. The authors 
suggest that the reason for their not finding toxicity despite exposing the 
mice to highly concentrated silver NPs for a sufficient amount of time was 
７due to accumulation or agglomeration between particles (22). Most 
nanoparticles that are actually introduced into the body, whether by 
inhalation or by other methods of exposure, end up accumulating in the 
body. However, even if the size increases from accumulation, because they 
accumulate in varying sizes, it cannot be simply ignored. Researchers have 
also performed in vivo tests of the effect of silver NPs on zebra fish. 
Exposing zebra fish embryos to 30 to 72 nm silver nanoparticles resulted in 
nanoparticles spreading slowly within the embryos, which also exhibited
size-dependent nanotoxicity (23). 
Because of their small size, NPs that enter the human body can easily 
penetrate biological barriers (skin, intestines, lungs, etc.) and can be 
circulated throughout the entire body, ultimately reaching the vascular 
endothelium. Some studies have shown that inhaled nano-sized particles 
can move through the bloodstream and can spread to the lungs and other 
organs by passing freely between alveolar epithelial cells and the vascular 
endothelium through the gap fenestration pathway in the air-blood barrier, 
which has gaps of 0.03 – 3 µm (24). The endothelium is the human body’s
first internal layer of blood vessels and is distributed throughout the entire 
body. Therefore, the first important aspect of the endothelium is that it 
allows molecules to move to and circulate through various tissues through 
blood flow. Moreover, the endothelium also controls certain pathways, such 
as lipid metabolism and vascular inflammation. When these functions are 
lost, vascular diseases may be triggered (25). These characteristics of the 
８endothelium are closely linked to the mechanism by which NPs infiltrate the 
human body and make their way to various organs. Accordingly, the 
present study makes a distinction between epithelial and endothelial cells in 
observing the toxic effects of silver NPs.
One study shows the effects of silver NPs at the cellular level and 
summarizes the present state of knowledge. As is the case with other 
nanoparticles, the most important apparent effect is oxidative stress. The 
enhanced generation of ROS affects the mitochondrial respiratory chain and 
increases the amount of unfolded and misfolded proteins in the endoplasmic 
reticulum, inducing ER stress and the unfolded protein response. Both 
these types of cellular damage lead to further ROS generation, DNA 
damage, and the activation of signaling resulting in various cell type-
specific pathways to inflammation, apoptosis, or necrotic death (26). 
Among these ROS pathways, the heat shock response is a major pathway 
by which the cells protect themselves from oxidative stress, and when cells 
are damaged, transcriptional upregulation of genes that encode heat shock 
proteins (HSPs) occurs. HSPs are known as molecular chaperones that 
play an essential role in folding nascent proteins and deleting misfolded 
proteins (27). Moreover, HSPs are also involved in regulating mitochondrial 
membrane integrity, in the activation of caspase, and in various forms of 
cellular signaling, such as the apoptotic signaling pathway (28). Among 
HSPs, HSPs that are elevated by stress (HSPA1A, HSP70) are upregulated 
by pathophysiological stressors like ischemia and have also been reported 
９to show increased expression from environmental stressors like air 
pollutants (29, 30, 31). Expression of HSP responds sensitively to stress, 
and thus is commonly used as a potential biomarker for toxicity.  
Heme oxygenase 1 (HO-1) is an inducible enzyme that primarily 
performs antioxidant and anti-inflammation functions (32). HO-1 is 
upregulated by various oxidizing agents, heavy metals, pro-inflammatory 
cytokines, and hypoxia (33, 34, 35). In one study it was shown that 
bilirubin and carbon monoxide (CO) could be produced by inducing anti-
inflammation through the catalytic action of HO-1 (36). Therefore, HO-1 
acts as an important factor that protects cells from oxidative stress. 
Accordingly, the present study aimed to use levels of HSP70 and HO-1 
expression in explaining the oxidative stress response generated when
exposing cells to the causative substance of silver NPs.
Cytokines are small secreted proteins that control interaction and 
signaling between cells. Cytokines that play an important role in cell 
signaling include lymphokines (cytokines produced by lymphocytes), 
monokines (cytokines produced by monocytes), chemokines (cytokines 
with chemotactic activities), and interleukins (ILs, cytokines produced by 
leukocytes to affect the behavior of other leukocytes; however, at present 
it is clear that all cells are able to secrete cytokines). Although cytokines 
are secreted from a wide variety of cells, they are secreted in distinctly 
higher concentrations from helper T cells and macrophages (37). Cytokines 
possess both pro- and anti-inflammatory properties, but their roles 
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change slightly depending on the situation. Some cytokines, such as 
interleukin (IL)-1β, IL-6 and TNF-α, function as pro-inflammatory 
cytokines and accompany pathological pain. Chemokines increase 
chemotaxis, while other cytokine groups show anti-inflammatory effects. 
IL-1 receptor antagonists (IL-4, IL-10, IL-11, and IL-13) are the 
primary anti-inflammatory cytokines (37). 
IL-11 is a member of the IL-6 family of cytokines and has various 
functions. The IL-6 family of cytokines includes not only IL-11 but also
IL-6, IL-27, IL-31, leukemia inhibitory factor, ciliary neurotrophic factor, 
oncostatin M, and cardiotrophin-1 (38). IL-6 is associated with chronic 
inflammatory diseases and is responsible for the progression of various 
types of cancer. It activates the signal transducer and the activator of 
transcription 3 (STAT3) pro-survival pathways. According to one study, 
IL-6 and IL-11 were responsible for advancing gastrointestinal cancer, 
and during this process IL-11 was found to be closely associated with 
STAT3 activation (39). IL-11 performs hematopoietic functions in in many 
different areas of the body, including the liver, the gastrointestinal tract, 
the lungs, the heart, the central nervous system, the bones, the joints, and
the immune system (40). Playing a protective role by accelerating platelet 
recovery and reducing inflammatory responses, IL-11 was able to lower 
the mortality rate among sepsis patients (41). In other words, among the 
immune responses of IL-11, anti-inflammatory properties were also 
identified. Consequently, the various functions and roles of IL-11 are 
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drawing new attention. Other biological activities of IL-11 include 
stimulation of erythropoiesis and activation of megakaryocytes. Moreover, 
it controls the polarization of T cells and macrophages and promotes the
maturation of bone resorbing osteoclasts (42). In addition, it also plays a 
role in neurogenesis (43), adipogenesis (44), and promotion of stem cell 
development (45), while also protecting cells from graft versus host 
disease (46) and blocking gastric acid secretion (47). Finally, IL-11 
performs a variety of functions in various cells. In the epithelial cells 
examined in the present study, IL-11 reduces proliferation and induces 
apoptosis. Moreover, in endothelial cells it plays a role in cell activation and 
in the expression of surviving proteins that are involved in cell proliferation. 
IL-11 also affects mast cells, inducing proliferation. Moreover, in 
macrophages and osteoclasts, respectively, IL-LL reduces the production 
of IL-1β, IL-12, NO, NF-κB and decreases formation, increases bone 
resorption (48).
Based on the above, the present study aimed to identify different types of 
cell responses by distinguishing between endothelial and epithelial cells and 
exposing them to silver NPs. The study also aimed to describe the 
progression of cell apoptosis from the occurrence of intracellular oxidative 
stress caused by silver NPs and to identify which genes are being 
stimulated to cause such changes. We also assessed several gene 
expression levels that increased significantly in the microarray assay. 
These results provide important insight to help understand and identify the 
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effects of silver NPs.
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2. Materials and Methods
2.1. Effects of silver NPs on endothelial cells (EA.hy926)
2.1.1. Silver NPs
Silver NPs in water-based solutions were obtained from Dr. Koh (5 nm; 
PNM, Hwaseong, Korea) or purchased from ABC Nanotech (100 nm; 
Daejeon, Korea). Silver NPs (5 nm and 100 nm) were synthesized by the 
reduction of AgNO3. All silver NPs were round and PVP-coated. Endotoxin 
contamination tests were conducted using the Pyrotell®-T kinetic 
turbidimetric method (Associates of Cape Cod, Inc., MA, USA), and the 
results were negative (endotoxin < 0.01 U/mL). For cell culture, different 
concentrations of silver NPs were prepared in high glucose Dulbecco's 
Modified Eagle’s Medium (DMEM; Welgenen, Gyeongsan, Korea) with 2 
mM L-glutamine supplemented with 10% fetal bovine serum (FBS; 
Welgenen), 100 U/mL penicillin, and 100 ㎍/mL streptomycin.
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2.1.2. Characterization of silver NPs
The diameter of the silver NPs was determined using a transmission 
electron microscope (TEM; model JEM-2010, JEOL Ltd., Tokyo, Japan). 
Agglomeration of the NPs in DMEM with 10% FBS at 0.5 ㎎/mL was 
examined by dynamic light scattering (DLS; Malvern Instruments, Novato, 
CA, USA).
2.1.3. Cell lines and culture
The human umbilical vein cell line, EA.hy926 (ATCC, Manassas, VA, 
USA), was established by fusing primary human umbilical vein cells with a 
thioguanine-resistant clone of A549 by exposure to polyethylene glycol 
(PEG). EA.hy926 cells were cultured in DMEM containing 10% FBS and 
penicillin-streptomycin (100 U/mL and 100 ㎍/mL, respectively) at 37℃
in a humidified 5% CO2 atmosphere in an incubator. The culture medium 
was changed every two to three days to maintain cell density at 
approximately 1 × 105 cells/cm2. Although endotoxins were not detected 
in the silver NPs used in this study, polymyxin B (InvivoGen, San Diego, 
CA, USA) at a concentration of 10 ng/mL was added as an endotoxin 
neutralizer. 
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2.1.4. Analysis of cell proliferation
Cell viability was assessed using the colorimetric cell counting kit-8 
(CCK-8; Dojindo Laboratories, Kyoto, Japan). CCK-8 is a colorimetric 
assay that uses a highly water soluble tetrazolium salt, WST (8[2-(2-
methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-
2H-tetrazolium, monosodium salt]). Cells were plated in 24-well plates at 
a density of 5 × 104 cells per 500 µL of growth medium per well and 
incubated overnight in a 5% CO2 incubator. The medium was removed and 
the cells were treated with 500 µL of silver NP solution diluted in the 
growth medium. After 24 h, 15 µL of the CCK-8 reagent was added to 
each well and then incubated at 37℃ for 2 h. After 13,000 rpm, 5 min 
centrifugation, 200 µL of supernatant was transferred to 96-well microtiter 
plates and the optical density (O.D) was measured at 450 nm with a 
spectrophotometer (BioTek Instruments, Winooski, VT, USA) to ensure 
that there was no optical interference by silver NPs.
2.1.5. Cytokine detection
Enzyme-linked immunosorbent assay (ELISA) was used to detect the 
presence of the cytokines IL-8 and IL-11. EA.hy926 cells were plated in 
6-well plates at a density of 1.5 × 105 cells per well in 2 mL of DMEM 
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containing 10% FBS. The medium was removed and the silver NPs 
suspended in the medium were added to each well, to a final volume of 1 
mL per well. These wells were then incubated for 8 h (for IL-8 assay) and 
24 h (for IL-11 assay). After 8 h, the cell culture supernatant was 
collected and stored at −80℃. ELISA was performed using a human 
cytokine IL-8 assay kit (BD Biosciences, San Diego, CA, USA). After 24 h, 
the cell culture supernatant was collected and stored at −80℃. ELISA was 
performed using a human cytokine IL-11 assay kit (R&D Systems, 
Minneapolis, MN, USA). These kits use biotinylated anti-IL-8 or anti-IL-
11 antibodies and streptavidin conjugated to horseradish-peroxidase. The 
O.D was measured at 450 nm.
2.1.6. Real-time reverse transcriptase polymerase chain reaction (RT-PCR)
cDNA was synthesized from total RNA via reverse transcription with 
random primers (Invitrogen, San Diego, CA, USA). Primer pairs designed 
to amplify the cDNA encoding the target genes were prepared using the 
Invitrogen Oligo Perfect Designer (Thermo Fisher Scientific, Waltham, 
Massachusetts, USA). PCR reactions were performed using FastStart 
Universal SYBR Green Master (ROX) reagent according to the 
manufacturer’s instructions (Roche Applied Science, Mannheim, Germany) 
in a 7500 and StepOne Plus Real-time PCR system (Applied Biosystems, 
Foster City, CA, USA). The reaction parameters were as follows: 2 min at 
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50℃, 10 min at 95℃, 40 cycles of denaturation at 95℃ for 15 s, and 60℃
for 1 min. Real-time RT-PCR data for each gene product were normalized 
against levels of glyceraldehyde 3-phosphate dehydrogenase (GAPDH). 
All transcript levels were reported as mean ± standard deviation (SD) 
relative to untreated controls from triplicate analyses. Gene expression 
levels were analyzed using the comparative CT Method with the fold 
difference calculated based on the endogenous control (GAPDH). Primer 
sequences were as follows: IL-8, forward: 5’-GTG CAG TTT TGC CAA 
GGA GT-3’ and reverse: 5’-CTC TGC ACC CAG TTT TCC TT-3’; 
IL-11, forward: 5’-CTG AGC CTG TGG CCA GAT A-3’ and reverse: 
5’-AGC TGT AGA GCT CCC AGT GC-3’; HO-1, forward: 5’-ATG 
ACA CCA AGG ACC AGA GC-3’ and reverse: 5’-GTG TAA GGA CCC 
ATC GGA GA-3’; HSP-70, forward: 5’- AGG CCA ACA AGA TCA 
CCA-3’ and reverse: 5’-TCG TCC TCC GCT TTG TAC TT-3’; 
GAPDH, forward: 5’-GAT CAT CAATGC CTC CT-3’ and reverse: 
5’-TGT GGT CAT GAG TCC TTC CA-3’. One-way analysis of 
variance (ANOVA) was used to assess differences between the control and 
experimental groups.
Formulae: ΔCT = CT target – CT GAPDH
ΔΔCT = ΔCT test sample - ΔCT control sample
S	(standard	deviation) = 	 (         +  
 
     )
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2.1.7. Western blot
For western blot analysis, 4.5 × 105 EA.hy926 cells were seeded into 
60-mm Petri dishes. Cells were then treated with 5 nm and 100 nm silver 
NPs for 24 h. Cells were harvested and lysed at 4℃ for 2 h in 200 µL of 
lysis buffer (150 mM NaCl, 1% NP-40, 0.1% SDS, 50 mM Tris pH 8, 5 mM 
NaF, 1 mM Na3VO4, 1 mM PMSF, protease inhibitor cocktail). The cell 
lysates were centrifuged at 13,000 rpm for 15 min at 4℃ and the 
supernatants were stored at −20℃. Protein concentrations in the lysates 
were measured using the Bradford assay. From each sample, 30–40 ㎍ of 
protein was boiled for 5 min and loaded on a 12% sodium dodecyl sulfate 
(SDS)-polyacrylamide gel. After electrophoresis, proteins in the gel were 
transferred onto nitrocellulose membranes (Amersham, Glattbrugg, 
Switzerland). After blocking with 5% skim milk (BD Biosciences, Franklin, 
NJ, USA), membranes were reacted with primary antibodies such as anti-
HO-1 antibodies (Cell Signaling Technology, Danvers, MA, USA) and anti-
HSP-70 antibodies (Cell Signaling Technology) at 1:1000 dilution in 5% 
bovine serum albumin (BSA) (Affymetrix, Cleveland, Ohio, USA) at 4℃
overnight. After washing, the membranes were further reacted with a 
secondary antibody (peroxidase-conjugated affinipure goat anti-rabbit IgG, 
Jackson ImmunoResearch, West Grove, PA, USA) at 1:2000 dilution in 5% 
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skim milk at room temperature for 1 h. Protein bands were detected using a 
Westsave up western blot detection kit (Ab Frontier, Seoul, Korea). An 
anti-GAPDH antibody (Cell Signaling Technology) was used to assess 
transcription levels of housekeeping genes. The membranes were exposed
to X-ray film (Fujifilm, Tokyo, Japan). Each band was analyzed using the 
software ImageJ (https://imagej.nih.gov/ij/). Fold induction was calculated 
as follows: fold induction = densitometric value of study group / 
densitometric value of control group.
2.1.8. Transmission electron microscopy (TEM) analysis
EA.hy926 cells treated with 1.5 ㎍/mL of 5 nm and 100 nm silver NPs for 
30 min were fixed with Karnovsky solution (2.5% glutaraldehyde, 2% 
paraformaldehyde, 0.5% CaCl2) for 1 h and then washed three times with 
PBS buffer. Cells were treated with 1% OsO4 in 0.1 M PBS buffer for 2 h. 
The monolayers of cells were dried through a graded alcohol series for 10 
min each, followed by a final addition of propylene oxide for 10 min. 
Samples were then treated with a mixture of EPON (EPON 812, MNA, 
DDSA, DMP30) and propylene oxide (1:1) for 18 h and heated in an 
embedding oven at 35℃ for 6 h, 45℃ for 12 h, and 60℃ for 24 h. The cell 
blocks were trimmed and sectioned at 0.25 µm using an ultramicrotome 
(Leica Ultracut UCT, Leica Microsystems GmbH, Wetzlar, Germany). 
These ultra-thin sections were stained with 1% toluidine blue and put on a 
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copper grid. The samples were then stained with uranyl acetate (6%) and 
lead citrate and analyzed using a TEM (JEM-1011, JEOL, Tokyo, Japan).
2.1.9. RNA isolation and cDNA microarray analysis
Total RNA was extracted using the RNeasy® Mini Kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s guidelines. RNA quantity was 
measured using a Nanodrop ND-1000 spectrophotometer (Wilmington, DE, 
USA), and an RNA 260/280 ratio of 1.8–2.1 was used for all samples. 
Whole genome microarray analysis was performed using an Affymetrix 
GeneChip® Human Gene 2.0 ST Array (Affymetrix, CA, USA). This array 
can analyze the transcription of 24,838 RefSeq (Entrez) genes. EA.hy926 
cells were plated on 60-mm Petri dishes (4.5 × 105 cells) overnight and 
then exposed to 1.5–2 ㎍/mL of 5 nm or 100 nm silver NPs for 6 h. cDNA 
was synthesized from 3 ㎍ of total RNA in the presence of a random 
primer. In vitro transcription reactions were performed with a mixture of 
biotin-labeled ribonucleotides to create biotinylated cRNAs from the cDNA 
templates. Fluorescence intensities captured using an Affymetrix 
GeneChip® Scanner 3000 7G were extracted using the Affymetrix 
GeneChip® Command Console® Software (AGCC), converted to an absolute 
fold change scale, and standardized and normalized using the Robust Multi-
array Average (RMA) algorithm, which normalizes the distribution of probe 
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intensities for all gene arrays in a given set. Gene expression values were 
median-centered and imported into the Expression Console 1.4 software. 
Principal component analysis was performed to verify the consistency of 
the experiments in order to determine if there were any chip outliers. 
Transcripts with a 1.5-fold or higher change in their expression values 
were selected, and a t-test was used to evaluate the significance of 
differences (p < 0.05).
Table 1. GeneChip® Human Gene 2.0 ST Array Specifications
Transcript coverage of the array
NM - RefSeq coding transcript, well-established annotation 30,654
NR - RefSeq non-coding transcript, well-established annotation 5,638
XM – RefSeq coding transcript, provisional annotation 996
XR – RefSeq non-coding transcript, provisional annotation 3,428
Total RefSeq transcripts 40,716
RefSeq (Entrez) gene count 24,838
lincRNA transcripts1 11,086
1 Derived from the Broad Institute’s Human Body Map lincRNAs and TUCP (transcripts 
of uncertain coding potential) catalog and lncRNA db
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2.1.10. Statistical analysis
Data are expressed as the mean ± SD. The statistical comparisons were 
performed using one-way ANOVA for two groups and two-way ANOVA 
with Bonferroni post-tests for more than two groups. Statistical analyses 
were performed using GraphPad Prism 5 (GraphPad Software, CA, USA). 
cDNA microarray results were analyzed using independent t-tests. A p-
value < 0.05 was considered significant. 
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2.2. Effects of silver NPs on bronchial epithelial cells (BEAS-2B)
2.2.1. Cell lines and culture
The human bronchial epithelial cell line, BEAS-2B (ATCC, Manassas, VA, 
USA), was isolated from normal human bronchial epithelium obtained from 
autopsy of non-cancerous individuals. BEAS-2B cells were cultured in 
Minimum Essential Medium (MEM; Welgenen, Gyeongsan, Korea) 
containing 10% FBS and penicillin-streptomycin (100 U/mL and 100 ㎍/mL, 
respectively) at 37℃ in a humidified 5% CO2 incubator. Fresh culture 
media was added every two to three days. Although endotoxins were not 
detected in the silver NPs used in this study, polymyxin B at a 
concentration of 10 ng/mL was added as an endotoxin neutralizer.
2.2.2. Analysis of cell proliferation
Cell viability was assessed using the CCK-8 kit. Cells were plated in 24-
well plates at a density of 6 × 104 cells in 500 µL of growth medium per 
well and incubated overnight in a 5% CO2 incubator. The medium was then 
removed and the cells were treated with 500 µL of silver NP solution 
diluted in 2% FBS growth medium. After 24 h, 15 µL of CCK-8 reagent 
was added to each well and then incubated at 37℃ for 2 h. After 13,000 
rpm, 5 min centrifugation, 100 µL of supernatant was transferred to 96-
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well microtiter plates and the O.D was measured at 450 nm with a 
spectrophotometer to ensure that there was no optical interference by 
silver NPs.
2.2.3. Cytokine detection
BEAS-2B cells were plated in 6-well plates at a density of 2 × 105 cells 
per well in 2 mL of MEM containing 10% FBS. The medium was then 
removed and silver NPs in 2% FBS growth medium were added to each 
well, to achieve a final volume of 1 mL per well. These wells were 
incubated for 8 h (IL-8 assay) and 24 h (IL-11 assay). After 8 h, the cell 
culture supernatant was collected and stored at −80℃ and the ELISA was 
performed using a human cytokine IL-8 assay kit. After 24 h, the cell 
culture supernatant was collected and stored at −80℃ and the ELISA was 
performed using a human cytokine IL-11 assay kit. These kits use 
biotinylated anti-IL-8 or anti-IL-11 detection antibodies and streptavidin 
conjugated to horseradish-peroxidase. The OD was measured at 450 nm.
2.2.4 Real-time RT-PCR
cDNA was synthesized from total RNA via reverse transcription with 
random primers. Primer pairs designed to amplify the cDNA encoding 
target genes were prepared using the Invitrogen Oligo Perfect Designer. 
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PCR reactions were performed using FastStart Universal SYBR Green 
Master (ROX) reagent according to the manufacturer’s instructions in a 
7500 and StepOne Plus Real-time PCR system.
2.2.5. Western blot
For western blot analysis, 3.5 × 105 BEAS-2B cells were seeded into 
60-mm Petri dishes. The cell lysates were centrifuged at 13,000 rpm for 
15 min at 4℃ and, the supernatant was stored at −20℃. The protein 
concentrations of the lysates were measured using the Bradford assay. 
From each sample, 30–40 ㎍ of protein was boiled for 5 min and loaded on 
a 12% SDS-polyacrylamide gel. After electrophoresis, proteins were 
transferred onto nitrocellulose membranes (Amersham, Glattbrugg, 
Switzerland). After blocking with 5% skim milk, the membranes were 
reacted with primary antibodies such as anti-HO-1 and anti-HSP-70 at
1:1000 dilution in 5% BSA at 4℃ overnight. After washing, the membranes 
were further reacted with secondary antibody (Goat Anti-Rabbit IgG; 
Jackson ImmunoResearch, PA, USA) at 1:2000 dilution in 5% skim milk at 
room temperature for 1 h. An antibody to the housekeeping gene GAPDH 
was used as an internal control.
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2.2.6. RNA isolation and cDNA microarray analysis
Total RNA was extracted using the RNeasy® Mini Kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s guidelines. Whole genome 
microarray analysis was performed using an Affymetrix GeneChip® Human 
Gene 2.0 ST Array. BEAS-2B cells were plated on 60-mm Petri dishes
(3.5 × 105 cells) overnight and then exposed to 0.5 ㎍/mL of 5 nm or 100 
nm silver NPs for 6 h. cDNA was then synthesized from 3 ㎍ of total RNA 
in the presence of a random primer. Transcripts with a 2-fold or higher 
change in their expression values were selected for further analysis.
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3. Results
3.1 Characterization of silver NPs
Characterization of the silver NPs used in this experiment is shown in 
Figure 1. The size of the silver NPs was determined using TEM. The 5 nm 
silver NPs were comparatively consistent in size, but the size of the 100
nm silver NPs varied. Particle shape was round (Figure 1A). Dynamic light 
scattering (DLS) analysis showed that the hydrodynamic diameter of silver 
NPs was 5.3 nm for the 5 nm silver NPs and 74.2 nm for the 100 nm silver 
NPs (Figure 1B). DLS analysis of the size distribution of the silver NPs in 
DMEM medium containing 10% FBS produced a bell-shaped curve. Silver 
NPs were suspended in 10% FBS growth medium and 2% FBS growth 
medium for use with endothelial cells (EA.hy926) and epithelial cells 
(BEAS-2B), respectively. Silver NPs in the growth medium retained 
excellent dispersion and stability, and were thus suitable for further 
experimentation.
When spectrophotometric data are collected in nanomaterial experiments 
such as CCK-8 and ELISA assays, it must be verified that the NPs do not 
hinder the absorbance of the indicator system. Silver NPs can influence the 
optical density at high concentrations, and have a lesser effect at low 
concentrations (Figure 2). Therefore, optical density results must be 
corrected using a silver-NP-only sample.
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Figure 1. Analysis of silver NPs. (A) TEM images of silver NPs showed 5 
nm silver NPs are relatively uniform in sizes, but, 100 nm silver NPs 
showed a range of different sized particles. (B) DLS analysis showed that 
the mean size of the 5 nm silver NPs was 5.3 nm and that of the 100 nm
NPs was 74.2 nm. Silver NPs were dispersed in DMEM medium containing 
10% FBS for DLS. 
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Figure 2. Influence of silver NPs on spectrophotometric analysis. Silver NPs 
(5 nm) were serially diluted in cell culture medium and the optical density 
was assessed at 405, 450, 490 nm, respectively.
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3.2. Effects of silver NPs on endothelial cells
3.2.1. Cytotoxicity in endothelial cells
Viability assays are an essential step in toxicology that reveals the 
cellular reaction to a potential toxicant. In the present study, endothelial 
cells (EA.hy926) were treated with silver NPs for 24 h and cell viability 
was determined using a CCK-8 assay. As shown in Figure 3, cell viability 
decreased as the concentration of 5 nm silver NPs increased. At 
concentrations of 1, 1.5, 2, 2.5, 2.75, 3, and 3.5 ㎍/mL, cell viability was 
reduced to 91%, 69%, 26%, 8%, 4%, 3%, and 1%, respectively; viability 
was significantly lower than the control. The LD50 of the 5 nm silver NPs 
was approximately 1.72 ㎍/mL. However, the 100 nm silver NPs did not 
show cytotoxicity at up to 3.5 ㎍/mL (Figure 3). These results showed the 
toxicity of silver NPs to EA.hy926 is size and dose-dependent.
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Figure 3. Cytotoxicity of silver NPs to endothelial cells. EA.hy926 cells 
were treated with 5 nm or 100 nm silver NPs for 24 h, and cytotoxicity 
was determined using a CCK-8 assay. The LD50 of the 5 nm silver NPs 
was approximately 1.72 ㎍/mL. Data represent the mean ± SD of three 
independent experiments. One-way and two-way ANOVAs were used to 
determine significance (***p < 0.001).
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3.2.2. cDNA microarray analysis 
Microarray analysis was used to detect changes in gene expression. 
cDNA for microarray analysis was collected after 6 h of exposure to silver 
NPs at near the LD50 concentration, in order to detect changes in gene 
expression at a dose that does not produce obvious cell damage. In this 
study, the Affymetrix GeneChip® Human Gene 2.0 ST Array was used. It is 
capable of analyzing 24,838 RefSeq (Entrez) genes with a total of 40,716 
RefSeq transcripts. Microarray data are expressed as absolute fold change 
values, where each unit indicates a 1.5-fold change in expression level. 
Table 2 shows a summary of the differentially expressed gene (DEG) 
count data at 6 h post–silver NP exposure. In the DEG summary data, a 
1.5-fold increase is equivalent to a doubling of expression and a 1.5-fold 
decrease is equivalent to a halving of expression. The Venn diagram shows 
that 466 genes differed in positive expression between cells exposed to 5 
nm silver NPs and controls, 27 genes differed in positive expression 
between cells exposed to 100 nm silver NPs and controls, and 479 genes 
differed in positive expression between cells exposed to 100 nm silver NPs 
and 5 nm silver NPs (Figure 4). Selected genes with a positive absolute 
fold change of 2.0 or greater in 5 nm silver NP–treated cells include those 
associated with oxidative stress and cytokine production (Table 3). As 
shown in Table 3A, the gene with the highest fold change (47.9-fold) was 
metallothionein 1G. Heme oxygenase (decycling) 1 and heat shock 70 kDa 
protein 1B showed 13.3-fold and 5.1-fold changes in expression, 
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respectively, which were significantly higher than the control. Additionally, 
as shown in Table 3B, which compares gene expression between cells 
exposed to 100 nm and 5 nm NPs, metallothionein 1G showed the highest 
fold change (44.3-fold). Furthermore, heme oxygenase (decycling) 1 and 
heat shock 70 kDa protein 6 (HSP70B) showed 11.5-fold and 5.2-fold 
changes in expression, respectively, which were significantly higher than 
expression induced by 100 nm silver NPs. Another interesting finding is 
that IL-11 expression was increased 10.4-fold. Although IL-8, IL-36α
and IL-1α also increased 6.1-fold 4.6-fold and 2.6-fold, respectively, 
the change in expression of IL-11 was the most prominent (Table 3A). 
The absolute fold change of IL-11 was 11.0-fold between the 100 nm
silver NPs and 5 nm silver NPs treatments. However, treatment with 5 nm 
silver NPs did not changed expression of IL-11 receptor (IL11RA) and 
CXCR1 by -1.0-fold and -1.1-fold, respectively. Significantly changed 
interleukin receptors were IL1RL1, IL7R and IL13RA2 (Table 4). Figure 5 
shows a heat map for the results for IL-11, HSP70, MT1G, and HO-1 
based on the microarray results. Genes were filtered for absolute fold 
change > 1.5. Red indicates high expression and green indicates low 
expression. 
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Table 2. DEG (Differentially Expressed Gene) summary
Group
Up-
regulation
Down-
regulation
Total 
genes
control vs. 5 nm 466 193 659
control vs. 100 nm 27 20 47
100 nm vs. 5 nm 479 181 660
Notes: Significant transcripts were selected when expression values changed by 1.5-fold or 
greater and while using a t-test with p-value < 0.05.
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Figure 4. Microarray analysis to determine expression changes in genes. 
The Venn diagram shows the number of genes with increased expression 
after exposure to silver NPs at approximately LD50 for 6 h at 2 ㎍/mL. Data 
from the Affymetrix GeneChip® include 24,838 RefSeq (Entrez) genes, and 
are presented on an absolute fold change scale, where each unit represents 
a 1.5-fold change in expression level. Results were analyzed using a t-
test and significance was set at p < 0.05.
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Table 3. List of increased genes after silver NPs exposure
(A) Control vs. 5 nm
Genes Fold Change p-value
metallothionein 1G 47.9 0.0008
long intergenic non-protein coding RNA 622 15.1 0.0079
heme oxygenase (decycling) 1 13.3 0.0001
putative novel transcript 11.3 0.0189
interleukin 11 10.4 0.0015
matrix metallopeptidase 10 (stromelysin 2) 8.7 0.0040
chemokine (C-X-C motif) ligand 8 6.1 0.0045
heat shock 70kDa protein 1B 5.1 0.0004
heat shock 70kDa protein 6 (HSP70B) 4.8 0.0027
metallothionein 1E 4.6 0.0008
"interleukin 36, alpha " 4.6 0.0292
heat shock 70kDa protein 1A 4.0 0.0006
"interleukin 13 receptor, alpha 2 " 3.8 0.0474
heat shock 70kDa protein 9 (mortalin) 3.5 0.0082
interleukin 1 receptor-like 1 3.1 0.0080
interleukin 7 receptor 2.7 0.0143
"interleukin 1, alpha " 2.6 0.0215
vascular endothelial growth factor A 2.4 0.0283
metallothionein 1X 2.3 0.0019
metallothionein 1F 2.2 0.0379
Notes: Significant transcripts were selected when expression values changed by 2-fold or 
greater and while using a t-test with p-value < 0.05.
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(B) 100 nm vs. 5 nm
Genes Fold Change p-vlaue
metallothionein 1G 44.3 0.0008
long intergenic non-protein coding RNA 622 18.1 0.0061
putative novel transcript 13.8 0.0140
heme oxygenase (decycling) 1 11.5 0.0001
interleukin 11 11.0 0.0013
"nuclear receptor subfamily 4, group A, member 1 
"
7.9 0.0003
matrix metallopeptidase 10 (stromelysin 2) 7.8 0.0028
chemokine (C-X-C motif) ligand 8 6.4 0.0008
heat shock 70kDa protein 6 (HSP70B) 5.2 0.0026
heat shock 70kDa protein 1B 5.0 0.0005
metallothionein 1E 4.3 0.0008
"interleukin 36, alpha " 4.0 0.0391
heat shock 70kDa protein 9 (mortalin) 3.9 0.0042
heat shock 70kDa protein 1A 3.9 0.0008
"interleukin 13 receptor, alpha 2 " 3.5 0.0479
interleukin 1 receptor-like 1 2.8 0.0108
spermine oxidase 2.8 0.0069
vascular endothelial growth factor A 2.6 0.0228
"interleukin 1, alpha " 2.6 0.0191
metallothionein 1X 2.3 0.0010
Notes: Significant transcripts were selected when expression values changed by 2-fold or 
greater and while using a t-test with p-value < 0.05.
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Table 4. List of changed interleukin receptor genes after silver NPs exposure
Genes Fold change Gene description p-value
IL1R1 1.3 interleukin 1 receptor, type I 0.1464
IL1R2 -1.0 interleukin 1 receptor, type II 0.7676
IL1RL1 3.1 interleukin 1 receptor-like 1 0.0080
IL1RL2 1.1 interleukin 1 receptor-like 2 0.3853
IL2RA 1.0 interleukin 2 receptor, alpha 0.7336
IL2RB 1.1 interleukin 2 receptor, beta 0.2867
IL2RG 1.1 interleukin 2 receptor, gamma 0.6365
IL3RA 1.1 interleukin 3 receptor, alpha (low affinity) 0.2973
IL4R 1.0 interleukin 4 receptor 0.3749
IL5RA 1.0 interleukin 5 receptor, alpha 0.4756
IL6R 1.1 interleukin 6 receptor 0.4765
IL7R 2.7 interleukin 7 receptor 0.0143
CXCR1 -1.1
chemokine (C-X-C motif) receptor 1 
(interleukin-8 receptor activity)
0.3498
IL9R -1.0 interleukin 9 receptor 0.4168
IL10RA 1.1 interleukin 10 receptor, alpha 0.2260
IL10RB -1.4 interleukin 10 receptor, beta 0.0056
IL11RA -1.0 interleukin 11 receptor, alpha 0.4038
IL12RB1 -1.1 interleukin 12 receptor, beta 1 0.7539
IL12RB2 -1.0 interleukin 12 receptor, beta 2 0.6158
IL13RA1 -1.0 interleukin 13 receptor, alpha 1 0.3480
IL13RA2 3.8 interleukin 13 receptor, alpha 2 0.0474
IL15RA -1.3 interleukin 15 receptor, alpha 0.1525
IL18R1 1.2 interleukin 18 receptor 1 0.1893
IL20RA -1.2 interleukin 20 receptor, alpha 0.2701
IL20RB 1.2 interleukin 20 receptor beta 0.1646
IL21R 1.0 interleukin 21 receptor 0.9211
IL22RA1 -1.2 interleukin 22 receptor, alpha 1 0.2303
IL22RA2 1.0 interleukin 22 receptor, alpha 2 0.8908
IL23R 1.1 interleukin 23 receptor 0.2603
IL27RA -1.3 interleukin 27 receptor, alpha 0.0726
Notes : control vs. 5 nm
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Figure 5. Hierarchical clustering. Heat map of genes showing differential 
expression in EA.hy926 cells based on microarray analysis. Genes were 
filtered for absolute fold change > 1.5. Red indicates high expression and 
green indicates low expression. (A) Untreated cell vs. 5 nm NP–treated 
cells. (B) 100 nm NP–treated cells vs. 5 nm NP–treated cells. Results were 
analyzed using a t-test and significance was set at p < 0.05.
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3.2.3. Classification of genes that showed increased expression following 
treatment with silver NPs
Next, we classified the genes with an absolute fold change of 1.5 or 
greater, comparing the microarray results for the 5 nm silver NPs and 100 
nm silver NPs. Genes were divided into five categories that showed 
increased gene counts based on gene ontology term: cell death (Table 5), 
cell survival (Table 7), inflammation (Table 11), apoptosis (Table 14), and 
ROS (Table 17). The cell death category includes genes involved in 
regulation of cell death. The number of genes regulating cell death was 37.
HO-1, HSP70 and IL-1α are included herein. As shown in Table 6, 
HMOX1, HSPA1B and IL1A showed 13.3-fold, 5.1-fold and 2.6-fold 
changes in expression, respectively, which were significantly higher than 
the control. The cell survival category included regulation of cell 
proliferation, regulation of endothelial cell proliferation and regulation of 
vascular endothelial growth factor production. The number of genes 
regulating cell proliferation was 20. HO-1, IL-11 and IL-1α are included 
herein. As shown in Table 8, HMOX1, IL-11 and IL1A showed 13.3-fold, 
10.4-fold and 2.6-fold changes in expression, respectively, which were 
significantly higher than the control. Also the number of genes regulating 
endothelial cell proliferation was 2 (Table 9). The number of genes 
regulating vascular endothelial growth factor production was 2. IL-1α is 
included herein (Table 10). The inflammation category included 
inflammatory response and genes involved in cytokines and inflammatory 
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response. The number of genes inflammatory response was 8. HO-1 and 
IL-1α are included herein (Table 12). In addition, the number of genes 
cytokines and inflammatory response was 2. IL-11 and IL-1α are 
included herein (Table 13). The apoptosis category included apoptotic 
mitochondrial changes and regulation of apoptosis. The number of genes 
regulation of apoptosis was 37. HO-1, HSP70 and IL-1α are included 
herein (Table 15). The number of genes apoptotic mitochondrial changes
was 2 (Table 16). Lastly, the ROS category includes genes involved in 
response to oxidative stress and ion binding. The number of genes 
response to oxidative stress was 8. HO-1 was included herein (Table 18). 
The number of genes ion binding was 67. As shown in Table 19, MT1G and 
HMOX1 showed 47.9-fold and 13.3-fold changes in expression, 
respectively, which were significantly higher than the control. The high fold 
change of MT1G is to be due to the silver NP belongs to the metal.
In particular, IL-11 was included in the cell survival and inflammation 
categories. These results suggest that the 5 nm silver NPs activated 
inflammation and ROS, as well as stimulating expression of cell proliferation 
genes. Most of the stress-related genes were included in the cell death, 
apoptosis, and ROS categories. 
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Table 5. Classification of increased genes associated with cell death 
categories
Ontology term Count
regulation of programmed cell death 37
regulation of cell death 37
negative regulation of programmed cell death 26
negative regulation of cell death 26
death 22
cell death 21
positive regulation of programmed cell death 12
positive regulation of cell death 12
programmed cell death 17
induction of programmed cell death 10
Notes: Significant transcripts were selected when expression values changed by 1.5-fold 
or greater and while using a t-test with p-value < 0.05.
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Table 6. Regulation of cell death genes
Fold 
Change
Gene 
Symbol
p-value Gene Description
13.3 HMOX1 0.0001 heme oxygenase (decycling) 1 
7.9 DDIT3 0.0046 DNA-damage-inducible transcript 3 
7.7 NR4A1 0.0004 "nuclear receptor subfamily 4, group A, member 1 "
5.1 HSPA1B 0.0004 heat shock 70kDa protein 1B 
5.1 PTGS2 0.0279 prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase
4.8 HSPA1B 0.0008 heat shock 70kDa protein 1B 
4.3 HSPA1B 0.0006 heat shock 70kDa protein 1B 
4.0 HSPA1A 0.0006 heat shock 70kDa protein 1A 
3.9 HSPA1A 0.0004 heat shock 70kDa protein 1A 
3.5 HSPA9 0.0082 heat shock 70kDa protein 9 (mortalin) 
3.5 HSPA1B 0.0001 heat shock 70kDa protein 1B 
3.5 BAG3 0.0013 BCL2-associated athanogene 3 
3.4 HSPA1A 0.0002 heat shock 70kDa protein 1A 
3.4 HSPA1A 0.0002 heat shock 70kDa protein 1A 
3.4 HSPA1A 0.0002 heat shock 70kDa protein 1A 
3.3 HSPA1A 0.0002 heat shock 70kDa protein 1A 
3.1 GCLM 0.0061 "glutamate-cysteine ligase, modifier subunit "
3.0 HERPUD1 0.0107
"homocysteine-inducible, endoplasmic reticulum stress-inducible, 
ubiquitin-like domain member 1 "
3.0 DEDD2 0.0482 death effector domain containing 2 
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2.9 NR4A2 0.0200 "nuclear receptor subfamily 4, group A, member 2 "
2.9 PMAIP1 0.0202
phorbol-12-myristate-13-acetate-induced 
protein 1 
2.6 IL1A 0.0215 "interleukin 1, alpha "
2.6 DNAJB6 0.0062 "DnaJ (Hsp40) homolog, subfamily B, member 6 "
2.4 VEGFA 0.0283 vascular endothelial growth factor A 
2.4 INHBA 0.0112 "inhibin, beta A "
2.3 CEBPB 0.0273 "CCAAT/enhancer binding protein (C/EBP), beta "
2.0 CRYAB 0.0218 "crystallin, alpha B "
2.0 SPHK1 0.0018 sphingosine kinase 1 
1.8
TNFRSF10
D
0.0113
"tumor necrosis factor receptor superfamily, member 10d, decoy 
with truncated death domain "
1.8 CEBPG 0.0359 "CCAAT/enhancer binding protein (C/EBP), gamma "
1.7 BCL2A1 0.0488 BCL2-related protein A1 
1.7 F3 0.0069 "coagulation factor III (thromboplastin, tissue factor) "
1.6 DAPK3 0.0124 death-associated protein kinase 3 
1.6 RB1CC1 0.0124 RB1-inducible coiled-coil 1 
1.6 ABL1 0.0230 "ABL proto-oncogene 1, non-receptor tyrosine kinase "
1.6 CLU 0.0022 clusterin 
1.5 SQSTM1 0.0171 sequestosome 1 
Notes: Significant transcripts were selected when expression values changed by 1.5-fold or 
greater and while using a t-test with p-value < 0.05.
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Table 7. Classification of increased genes associated with cell survival 
categories
Ontology term Count
cell proliferation 10
positive regulation of cell proliferation 14
regulation of cell proliferation 20
regulation of smooth muscle cell proliferation 4
positive regulation of smooth muscle cell proliferation 3
positive regulation of endothelial cell proliferation 2
positive regulation of fibroblast proliferation 1
regulation of endothelial cell proliferation 2
regulation of fibroblast proliferation 1
negative regulation of cell proliferation 6
positive regulation vascular endothelial growth factor production 2
regulation of vascular endothelial growth factor production 2
Notes: Significant transcripts were selected when expression values changed by 1.5-fold or 
greater and while using a t-test with p-value < 0.05.
４６
Table 8. Regulation of cell proliferation
Fold 
change
Gene 
Symbol
p-value Gene Description
13.3 HMOX1 0.0001 heme oxygenase (decycling) 1 
10.4 IL11 0.0015 interleukin 11 
5.1 PTGS2 0.0279
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H 
synthase and cyclooxygenase) 
4.0 LIF 0.0099 leukemia inhibitory factor 
3.5 ATF3 0.0228 activating transcription factor 3 
2.6 IL1A 0.0215 "interleukin 1, alpha "
2.6 DDR2 0.0194 discoidin domain receptor tyrosine kinase 2 
2.4 VEGFA 0.0283 vascular endothelial growth factor A 
2.3 TRIB1 0.0473 tribbles pseudokinase 1 
2.0 XIRP1 0.0101 xin actin-binding repeat containing 1 
2.0 MAFG 0.0163 v-maf avian musculoaponeurotic fibrosarcoma 
oncogene homolog G 
2.0 SPHK1 0.0018 sphingosine kinase 1 
1.9 NOX1 0.0092 NADPH oxidase 1 
1.7 VIP 0.0262 vasoactive intestinal peptide 
1.7 NAMPT 0.0322 nicotinamide phosphoribosyltransferase 
1.7 F3 0.0069 "coagulation factor III (thromboplastin, tissue factor) "
1.6 PROK1 0.0376 prokineticin 1 
1.6 KITLG 0.0097 KIT ligand 
1.6 CLU 0.0022 clusterin 
1.5 WARS 0.0399 tryptophanyl-tRNA synthetase 
Notes: Significant transcripts were selected when expression values changed by 1.5-fold or 
greater and while using a t-test with p-value < 0.05.
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Table 9. Regulation of endothelial cell proliferation
Fold 
Change
Gene 
Symbol
p-value Gene Description
2.4 VEGFA 0.0283 vascular endothelial growth factor A
1.7 F3 0.0069
"coagulation factor III (thromboplastin, 
tissue factor) "
Notes: Significant transcripts were selected when expression values changed by 1.5-fold or 
greater and while using a t-test with p-value < 0.05.
Table 10. Regulation of vascular endothelial growth factor production
Fold 
Change
Gene 
Symbol
p-value Gene Description
2.6 IL1A 0.0215 “interleukin 1, alpha”
1.9 NOX1 0.0092 NADPH oxidase 1 
Notes: Significant transcripts were selected when expression values changed by 1.5-fold or 
greater and while using a t-test with p-value < 0.05.
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Table 11. Classification of increased genes associated with inflammation 
categories
Ontology term Count
acute inflammatory response 4
inflammatory response 8
activation of plasma proteins involved in acute inflammatory response 2
Cytokines and Inflammatory Response 2
Notes: Significant transcripts were selected when expression values changed by 1.5-fold or 
greater and while using a t-test with p-value < 0.05.
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Table 12. Inflammatory response
Fold 
Change
Gene 
Symbol
p-value Gene Description
13.3 HMOX1 0.0001 heme oxygenase (decycling) 1 
4.1 KDM6B 0.0038 lysine (K)-specific demethylase 6B 
2.6 IL1A 0.0215 "interleukin 1, alpha "
2.3 CEBPB 0.0273 "CCAAT/enhancer binding protein (C/EBP), beta 
"
1.9 NOX1 0.0092 NADPH oxidase 1 
1.7 CYP4F11 0.0292
"cytochrome P450, family 4, subfamily F, 
polypeptide 11 "
1.7 F3 0.0069
"coagulation factor III (thromboplastin, tissue 
factor) "
1.6 CLU 0.0022 clusterin 
Notes: Significant transcripts were selected when expression values changed by 1.5-fold or 
greater and while using a t-test with p-value < 0.05.
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Table 13. Cytokines and Inflammatory Response
Fold 
Change
Gene 
Symbol
p-value Gene Description
10.4 IL11 0.0015 interleukin 11 
2.6 IL1A 0.0215 "interleukin 1, alpha "
Notes: Significant transcripts were selected when expression values changed by 1.5-fold or 
greater and while using a t-test with p-value < 0.05.
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Table 14. Classification of increased genes associated with apoptosis 
categories
Ontology term Count
apoptotic nuclear changes 1
apoptotic mitochondrial changes 2
regulation of apoptosis 37
anti-apoptosis 23
negative regulation of apoptosis 26
positive regulation of apoptosis 12
apoptosis 17
induction of apoptosis 10
DNA damage response, signal transduction resulting in induction of 
apoptosis
2
induction of apoptosis by intracellular signals 2
Neuropeptides VIP and PACAP inhibit the apoptosis of activated T cells 2
negative regulation of neuron apoptosis 2
regulation of neuron apoptosis 2
induction of apoptosis by extracellular signals 2
Notes: Significant transcripts were selected when expression values changed by 1.5-fold or 
greater and while using a t-test with p-value < 0.05.
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Table 15. Regulation of apoptosis
Fold 
Change
Gene 
Symbol
p-value Gene Description
13.3 HMOX1 0.0001 heme oxygenase (decycling) 1 
7.9 DDIT3 0.0046 DNA-damage-inducible transcript 3 
7.7 NR4A1 0.0004
"nuclear receptor subfamily 4, group A, member 1 
"
5.1 HSPA1B 0.0004 heat shock 70kDa protein 1B 
5.1 PTGS2 0.0279
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H 
synthase and cyclooxygenase) 
4.8 HSPA1B 0.0008 heat shock 70kDa protein 1B 
4.3 HSPA1B 0.0006 heat shock 70kDa protein 1B 
4.0 HSPA1A 0.0006 heat shock 70kDa protein 1A 
3.9 HSPA1A 0.0004 heat shock 70kDa protein 1A 
3.5 HSPA9 0.0082 heat shock 70kDa protein 9 (mortalin) 
3.5 HSPA1B 0.0001 heat shock 70kDa protein 1B 
3.5 BAG3 0.0013 BCL2-associated athanogene 3 
3.4 HSPA1A 0.0002 heat shock 70kDa protein 1A 
3.4 HSPA1A 0.0002 heat shock 70kDa protein 1A 
3.4 HSPA1A 0.0002 heat shock 70kDa protein 1A 
3.3 HSPA1A 0.0002 heat shock 70kDa protein 1A 
3.1 GCLM 0.0061 "glutamate-cysteine ligase, modifier subunit "
3.0 HERPUD1 0.0107
"homocysteine-inducible, endoplasmic reticulum stress-inducible, 
ubiquitin-like domain member 1 "
3.0 DEDD2 0.0482 death effector domain containing 2 
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2.9 NR4A2 0.0200
"nuclear receptor subfamily 4, group A, 
member 2 "
2.9 PMAIP1 0.0202
phorbol-12-myristate-13-acetate-induced 
protein 1 
2.6 IL1A 0.0215 "interleukin 1, alpha "
2.6 DNAJB6 0.0062
"DnaJ (Hsp40) homolog, subfamily B, 
member 6 "
2.4 VEGFA 0.0283 vascular endothelial growth factor A 
2.4 INHBA 0.0112 "inhibin, beta A "
2.3 CEBPB 0.0273
"CCAAT/enhancer binding protein (C/EBP), 
beta "
2.0 CRYAB 0.0218 "crystallin, alpha B "
2.0 SPHK1 0.0018 sphingosine kinase 1 
1.8 TNFRSF10D 0.0113
"tumor necrosis factor receptor superfamily, member 10d, decoy 
with truncated death domain "
1.8 CEBPG 0.0359
"CCAAT/enhancer binding protein (C/EBP), 
gamma "
1.7 BCL2A1 0.0488 BCL2-related protein A1 
1.7 F3 0.0069
"coagulation factor III (thromboplastin, tissue 
factor) "
1.6 DAPK3 0.0124 death-associated protein kinase 3 
1.6 RB1CC1 0.0124 RB1-inducible coiled-coil 1 
1.6 ABL1 0.0230
"ABL proto-oncogene 1, non-receptor 
tyrosine kinase "
1.6 CLU 0.0022 clusterin 
1.5 SQSTM1 0.0171 sequestosome 1 
Notes: Significant transcripts were selected when expression values changed by 1.5-fold or 
greater and while using a t-test with p-value < 0.05.
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Table 16. Apoptotic mitochondrial changes
Fold 
Change
Gene 
Symbol
p-value Gene Description
2.9 PMAIP1 0.0202
phorbol-12-myristate-13-acetate-
induced protein 1 
1.6 CLU 0.0022 clusterin 
Notes: Significant transcripts were selected when expression values changed by 1.5-fold or 
greater and while using a t-test with p-value < 0.05.
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Table 17. Classification of increased genes associated with ROS categories
Ontology term Count
response to reactive oxygen species 3
oxygen and reactive oxygen species metabolic process 2
response to oxidative stress 8
Oxidative Stress Induced Gene Expression Via Nrf2 4
cadmium ion binding 4
transition metal ion binding 54
zinc ion binding 45
copper ion binding 4
iron ion binding 7
magnesium ion binding 8
cation binding 67
ion binding 67
metal ion binding 65
manganese ion binding 3
calcium ion binding 5
Notes: Significant transcripts were selected when expression values changed by 1.5-
fold or greater and while using a t-test with p-value < 0.05.
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Table 18. Response to oxidative stress
Fold 
Change
Gene 
Symbol
p-value Gene Description
13.3 HMOX1 0.0001 heme oxygenase (decycling) 1 
7.9 DDIT3 0.0046 DNA-damage-inducible transcript 3 
5.1 PTGS2 0.0279
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H 
synthase and cyclooxygenase) 
3.1 GCLM 0.0061
"glutamate-cysteine ligase, modifier 
subunit "
2.2 SRXN1 0.0057 sulfiredoxin 1 
2.1 SELK 0.0223 selenoprotein K 
2.0 CRYAB 0.0218 "crystallin, alpha B "
1.6 CLU 0.0022 clusterin 
Notes: Significant transcripts were selected when expression values changed by 1.5-fold or 
greater and while using a t-test with p-value < 0.05.
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Table 19. Ion binding
Fold 
Change
Gene 
Symbol
p-value Gene Description
47.9 MT1G 0.0008 metallothionein 1G 
13.3 HMOX1 0.0001 heme oxygenase (decycling) 1 
8.7 MMP10 0.0040 matrix metallopeptidase 10 (stromelysin 2) 
7.7 NR4A1 0.0004
"nuclear receptor subfamily 4, group A, 
member 1 "
7.4 ZFAND2A 0.0001 "zinc finger, AN1-type domain 2A "
6.2 SLC30A1 0.0006
"solute carrier family 30 (zinc 
transporter), member 1 "
5.1 PTGS2 0.0279
prostaglandin-endoperoxide synthase 2 
(prostaglandin G/H synthase and 
cyclooxygenase) 
4.6 MT1E 0.0008 metallothionein 1E 
4.6 NR4A3 0.0030
"nuclear receptor subfamily 4, group A, 
member 3 "
4.1 KDM6B 0.0038 lysine (K)-specific demethylase 6B 
3.9 HIVEP2 0.0133
human immunodeficiency virus type I 
enhancer binding protein 2 
3.0 SNAI1 0.0047 snail family zinc finger 1 
2.9 RYBP 0.0062 RING1 and YY1 binding protein 
2.9 NR4A2 0.0200
"nuclear receptor subfamily 4, group A, 
member 2 "
2.9 JMJD1C 0.0182 jumonji domain containing 1C 
2.5 YOD1 0.0463 YOD1 deubiquitinase 
2.4 TES 0.0160 testis derived transcript (3 LIM domains) 
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2.4 GEM 0.0050
GTP binding protein overexpressed in 
skeletal muscle 
2.3 ZNF804A 0.0249 zinc finger protein 804A 
2.3 FBXO30 0.0007 F-box protein 30 
2.3 MT1X 0.0019 metallothionein 1X 
2.2 MT1F 0.0379 metallothionein 1F 
2.2 SRXN1 0.0057 sulfiredoxin 1 
2.0 SPHK1 0.0018 sphingosine kinase 1 
2.0 ZSWIM6 0.0121 "zinc finger, SWIM-type containing 6 "
1.9 ZCCHC6 0.0459 "zinc finger, CCHC domain containing 6 "
1.9 NOX1 0.0092 NADPH oxidase 1 
1.9 GCM1 0.0070 glial cells missing homolog 1 (Drosophila) 
1.9 SEC24A 0.0149 SEC24 family member A 
1.9 ABL2 0.0015
"ABL proto-oncogene 2, non-receptor 
tyrosine kinase "
1.9 ENTPD7 0.0205
ectonucleoside triphosphate 
diphosphohydrolase 7 
1.8 CRELD2 0.0419 cysteine-rich with EGF-like domains 2 
1.8 RAPGEF2 0.0039
Rap guanine nucleotide exchange factor 
(GEF) 2 
1.8 RPS6KA3 0.0266
"ribosomal protein S6 kinase, 90kDa, 
polypeptide 3 "
1.7 CSGALNACT2 0.0248 chondroitin sulfate N-acetylgalactosaminyltransferase 2 
1.7 ZNF175 0.0287 zinc finger protein 175 
1.7 GLA 0.0020 "galactosidase, alpha "
1.7 DNAJA1 0.0231
"DnaJ (Hsp40) homolog, subfamily A, 
member 1 "
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1.7 CYP4F11 0.0292
"cytochrome P450, family 4, subfamily F, 
polypeptide 11 "
1.7 ZBTB43 0.0435 zinc finger and BTB domain containing 43 
1.7 PGM3 0.0367 phosphoglucomutase 3 
1.7 ZNF697 0.0160 zinc finger protein 697 
1.7 ZNF460 0.0244 zinc finger protein 460 
1.7 ZNF34 0.0055 zinc finger protein 34 
1.6 EGR3 0.0026 early growth response 3 
1.6 JMJD6 0.0471 jumonji domain containing 6 
1.6 ME1 0.0143
"malic enzyme 1, NADP(+)-dependent, 
cytosolic "
1.6 ZFAND5 0.0068 "zinc finger, AN1-type domain 5 "
1.6 MBNL2 0.0004 muscleblind-like splicing regulator 2 
1.6 STK38L 0.0069 serine/threonine kinase 38 like 
1.6 GTF2B 0.0279 general transcription factor IIB 
1.6 PPP1R10 0.0407 "protein phosphatase 1, regulatory subunit 10 "
1.6 PPP1R10 0.0407 "protein phosphatase 1, regulatory subunit 10 "
1.6 PPP1R10 0.0407 "protein phosphatase 1, regulatory subunit 10 "
1.6 PPP1R10 0.0407 "protein phosphatase 1, regulatory subunit 10 "
1.6 BRF2 0.0453
"BRF2, RNA polymerase III transcription 
initiation factor 50 kDa subunit "
1.6 ABL1 0.0230
"ABL proto-oncogene 1, non-receptor 
tyrosine kinase "
1.5 SLC3A2 0.0158
"solute carrier family 3 (amino acid 
transporter heavy chain), member 2 "
1.5 PAPPA2 0.0483 pappalysin 2 
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1.5 LOC727896 0.0003
cysteine and histidine-rich domain 
(CHORD) containing 1 pseudogene 
1.5 PPP1R10 0.0439 "protein phosphatase 1, regulatory subunit 10 "
1.5 PPP1R10 0.0439 "protein phosphatase 1, regulatory subunit 10 "
1.5 PPP1R10 0.0439 "protein phosphatase 1, regulatory subunit 10 "
1.5 SQSTM1 0.0171 sequestosome 1 
1.5 ZNF384 0.0158 zinc finger protein 384 
1.5 DLL1 0.0465 delta-like 1 (Drosophila) 
1.5 ZNF876P 0.0288 "zinc finger protein 876, pseudogene "
Notes: Significant transcripts were selected when expression values changed by 1.5-fold or 
greater and while using a t-test with p-value < 0.05.
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3.2.4. Effects of silver NPs on cytokine production and the inflammatory 
response
EA.hy926 cells were treated with 5 nm and 100 nm silver NPs and 
cytokine production was assessed by ELISA. Endothelial cells were treated 
with different concentrations of silver NPs for 8 h (Figure 6A) and 24 h 
(Figure 6B). Because IL-8 is an earlier-responding cytokine, the two 
experiments used different treatment times. Supernatants harvested from 
control and silver NP–treated cells were assayed for IL-8 and IL-11. IL-8 
and IL-11 was the amount expressed in a concentration of 2.5 ㎍/mL for 5 
nm treatment group 1,000 pg/mL or more. The reason for decreased 
interleukin expression levels in a high concentration, because the cells are 
dead. As predicted, treatment with 100 nm silver NPs did not increase IL-
8 or IL-11 release. Thus, expression of cytokines increased in a size- and 
dose-dependent manner in response to silver NPs in endothelial cells. 
Furthermore, these results support the results of the cDNA microarray 
analysis.
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Figure 6. Dose-dependent expression of cytokines in response to silver NPs. 
(A) EA.hy926 cells treated with different doses of silver NPs for 8 h. (B) 
EA.hy926 cells treated with different doses of silver NPs for 24 h. Culture 
supernatant was harvested and the levels of IL-8 and IL-11 were 
measured by ELISA. Treatment with 5 nm silver NPs induced IL-8 and 
IL-11 release, but 100 nm silver NPs did not. Data represent the mean ±
SD of three independent experiments. One-way and two-way ANOVA 
analyses were used to determine significance (**p < 0.01, ***p < 0.001).
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3.2.5. Expression of genes related to cytokine production and ROS
IL-11, a gene found to be significantly increased by silver NP treatment 
in the cDNA microarray analysis, IL-8, HSP70 and HO-1 were included in 
the real-time RT-PCR analysis. Real-time RT-PCR analysis was 
performed after 6 h of exposure to 1.5 and 2 ㎍/mL of silver NPs. At 
concentrations of 1.5 and 2 ㎍/mL, IL-8 gene expression increased by 
3.5- and 6.5-fold, respectively. At the same concentrations, IL-11 gene 
expression by 2.9- and 6.2-fold, respectively (Figure 7A). In addition, at 
the same doses, HSP70 gene expression increased by 3- and 27-fold, 
respectively. Lastly, at these concentrations, HO-1 gene expression 
increased by 9.8- and 19.7-fold, respectively (Figure 7B). In concordance 
with the microarray data, genes related to cytokine production and ROS 
showed increased expression after treatment with 5 nm silver NPs. 
However, treatment with 100 nm silver NPs did not induce increased 
expression of IL-8, IL-11, HSP70, or HO-1. Thus, the microarray and 
real-time RT-PCR data were in accord. 
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Figure 7. Expression of cytokine- and ROS-related genes in endothelial 
cells treated with silver NPs. (A) Real-time RT-PCR analysis was 
performed for 6 h at 1.5 and 2 ㎍/mL of silver NPs. Expression of genes 
related to cytokine production increased after treatment with 5 nm silver 
NPs, but not after treatment with 100 nm silver NPs. (B) Expression of 
ROS-related genes. Real-time RT-PCR analysis was performed for 6 h at 
1.5 and 2 ㎍/mL of silver NPs. Exposure to 5 nm silver NPs induced 
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expression of HSP70 and HO-1. Exposure to 100 nm silver NPs did not 
induce the expression of HSP70 or HO-1. Real-time RT-PCR was 
performed three times and representative data are shown. Data are shown 
as the mean ± SD of three or more independent experiments. One-way 
and two-way ANOVA analyses were used to determine significance (*p< 
0.05, **p < 0.01, ***p < 0.001).
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3.2.6. Effects of silver NPs on HSP70 and HO-1 expression
For further verification, western blot analysis of two proteins (HSP70 and 
HO-1) was performed; the proteins were chosen based on the level of 
increased expression in response to treatment with 5 nm silver NPs. In 
accordance with the realtime-PCR results showed that RNA levels of 
HSP70 increased to a maximum of 27-fold and HO-1 increased to a 
maximum of 19.7-fold at 6 h-exposure. Therefore we tested the effect of 
silver NPs on the expression of HSP70 and HO-1 protein in EA.hy926 
cells. EA.hy926 cells were treated with different doses of silver NPs for 24 
h. Each 40-㎍ protein sample was loaded and analyzed using anti-HSP70, 
anti-HO-1, and anti-GAPDH (loading control) antibodies. HSP70 and 
HO-1 expression increased in cells treated with high-dose silver NPs 
compared to untreated cells. HSP70 protein levels increased by a maximum 
of 8.7-fold at 2.75 ㎍/mL (Figure 8A) and HO-1 protein levels increased 
by a maximum 33.5-fold at 3 ㎍/mL (Figure 8B) compared to the results 
for untreated cells. In contrast, ROS-associated proteins were not affected 
by treatment with 100 nm silver NPs. These results suggest that exposure 
to silver NPs could increase the expression of oxidative stress–related 
proteins. 
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Figure 8. Protein levels of HSP70 and HO-1 in endothelial cells treated with 
silver NPs. EA.hy926 cells were treated with different doses of silver NPs 
for 24 h. Each 40-㎍ protein sample was loaded and analyzed with anti-
HSP70, anti-HO-1, and anti-GAPDH (loading control) antibodies.
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3.2.7. Intracellular localization of silver NPs
The transportation and localization of silver NPs in EA.hy926 cells were 
observed by TEM. A representative image of one EA.hy926 cell treated 
with 1.5 ㎍/mL silver NPs for 30 min is shown. Untreated cells showed no 
abnormalities, but cells treated with 5 nm silver NPs showed internalization 
of NPs in vesicles (black arrow). Furthermore, mitochondrial swelling, 
decrease or disappearance of cytoplasm, and vacuolization were observed 
after treatment with 5 nm silver NPs. After treatment with 100 nm silver 
NPs, no clear changes in cell morphology were observed, even if the 
presence of NPs in lysosomes and the nucleus (Figure 9).
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Figure 9. Transmission electron microscopy (TEM) of endothelial cells after 
exposure to silver NPs. Representative ultrastructural images of one 
EA.hy926 cell treated with 1.5 ㎍/mL silver NPs for 30 min. (A) Untreated 
cells showed no abnormalities. (B) Cells treated with 5 nm silver NPs. NPs 
translocated into EA.hy926 cells. NPs internalized in vesicles (black arrow) 
are shown. (C) Cells treated with 100 nm silver NPs. No morphological 
abnormalities were observed, and NPs were localized in lysosomes and the 
nucleus. Images shown are representatives of three independent trials.
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3.3. Effects of silver NPs on bronchial epithelial cells
3.3.1. Cytotoxicity in bronchial epithelial cells
Epithelial cells (BEAS-2B) were treated with silver NPs for 24 h and cell 
viability was determined with the CCK-8 assay. As shown in Figure 10, 
cell viability decreased as the concentration of 5 nm silver NPs increased. 
At concentrations 0.5, 0.75, 1, 1.25, and 1.5 ㎍/mL, cell viability was 
reduced to 77%, 33%, 19%, 11%, and 5%, respectively: significantly lower 
than the control. The LD50 of 5 nm silver NPs was approximately 0.65 
㎍/mL. In contrast, 100 nm silver NPs did not show cytotoxicity at up to 1.5 
㎍/mL (Figure 10). These results showed that the toxicity of silver NPs to 
BEAS-2B cells is size and dose-dependent.
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Figure 10. Cytotoxicity of silver NPs in bronchial epithelial cells. BEAS-2B 
cells were treated with 5 nm or 100 nm silver NPs for 24 h, and 
cytotoxicity was determined with the CCK-8 assay. The LD50 of 5 nm
silver NPs was approximately 0.65 ㎍/mL. Data represent the mean ± SD 
of three independent experiments. One-way and two-way ANOVA 
analyses were used to determine significance (***p < 0.001).
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3.3.2. cDNA microarray analysis
Microarray analysis was used to detect changes in gene expression. 
cDNA for microarray analysis was collected after 6 h of exposure to silver 
NPs at 0.5 ㎍/mL to determine changes in gene expression that occur at a 
dose that does not produce obvious cell damage. In this study, the 
Affymetrix GeneChip® Human Gene 2.0 ST Array was used. Microarray 
data were assigned an absolute fold change value, where each unit indicates 
a 2-fold change in expression level. Table 20 shows DEG counts summary 
data after 6 h of silver NP exposure. DEG summary data are shown as 
numerical values for which a 2-fold increase is equivalent to a doubling of 
expression and a 2-fold decrease, to a halving of expression. The Venn 
diagram shows that 718 genes showed differences in expression between 
the control and 5 nm silver NP treatments, 26 genes differed between the 
control and 100 nm silver NP treatments, and 787 genes differed between 
the 100 nm silver NP and 5 nm silver NP treatments. The increased 
expressed gene in common in the three groups is three, which is the MT1E, 
MT1B and solute carrier family30 (zinc transporter) member 1 (Figure 11). 
Genes with greater than 2-fold positive change in their absolute 
expression levels include those associated with oxidative stress and 
cytokine production in cells treated with 5 nm silver NPs (Table 21). As 
shown in Table 21 (A), the activity-regulated cytoskeleton-associated 
protein showed the highest fold change (46.1-fold). The levels of the heat 
shock 70 kDa protein 7, heme oxygenase (decycling) 1, and metallothionein 
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1B were 36.4-fold, 18.1-fold, and 12.8-fold higher than those in the 
controls, respectively; which were significantly higher than the control.
Additionally, as shown in Table 21 (B), which compares gene expression 
between cells exposed to 100 nm and 5 nm NPs, activity-regulated 
cytoskeleton-associated protein showed the highest fold change (48.0-
fold). In addition, the expression levels of the heat shock 70 kDa protein 7, 
heme oxygenase (decycling) 1, and metallothionein 1G were 28.9-fold, 
12.6-fold and 6.0-fold increased, respectively. These genes showed 
higher expression in cells treated with 5 nm silver NPs than in cells treated 
with 100 nm silver NPs. Another interesting finding is that IL-8 and IL-11 
expression were increased 9.8-fold and 6.2-fold, respectively (Table 21
(A)). IL-8 and IL-11 showed 11.5-fold and 6.0-fold differences in 
expression between 100 nm silver NP and 5 nm silver NP-treatments. 
However, treatment with 5 nm silver NPs did not changed expression of 
IL-11 receptor (IL11RA) and CXCR1 by -1.2-fold and 1.1-fold, 
respectively. Significantly changed interleukin receptors were IL1RL1 and 
IL6R (Table 22). Changes in the expression of IL-8, IL-11, heat shock 
protein 70 kDa, metallothionein 1G, and heme oxygenase (decycling) 1, 
based on microarray results, are shown as a heat map (Figure 12). Genes 
were filtered for absolute fold change > 2. Red indicates high expression 
and green indicates low expression. 
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Table 20. DEG (Differentially Expressed Gene) summary
Group
Up-
regulation
Down-
regulation
Total 
genes
control vs. 5 nm 726 242 968
control vs. 100 nm 39 55 94
100 nm vs. 5 nm 821 251 1,072
Notes: Significant transcripts were selected when expression values changed by 2-fold.
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Figure 11. Microarray analysis to determine changes in expression of genes. 
Venn diagram showing the number of genes with increased expression 
after exposure to 0.5 ㎍/mL silver NPs for 6 h. Data from the Affymetrix 
GeneChip® includes 24,838 RefSeq (Entrez) genes, and is presented on an 
absolute fold change scale, where each unit represents a 2-fold change in 
expression level.
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Table 21. List of increased genes after silver NPs exposure
(A) Control vs. 5 nm
Genes Fold Change
activity-regulated cytoskeleton-associated protein 46.1
heat shock 70kDa protein 7 (HSP70B) 36.4
heme oxygenase (decycling) 1 18.1
metallothionein 1B 12.8
metallothionein 1E 12.7
heat shock 70kDa protein 6 (HSP70B') 11.1
interleukin 8 9.8
metallothionein 1G 6.8
interleukin 11 6.2
interleukin 1 receptor-like 1 5.4
metallothionein 1M 5.1
heat shock 70kDa protein 1B 4.2
BCL2-associated athanogene 3 3.7
heat shock 70kDa protein 1A 3.5
cytochrome P450, family 4, subfamily F, polypeptide 11 3.4
heat shock 70kDa protein 9 (mortalin) 3.4
VGF nerve growth factor inducible 3.1
oxidative stress responsive serine-rich 1 2.7
heparin-binding EGF-like growth factor 2.6
Smad nuclear interacting protein 1 2.4
Notes: Significant transcripts were selected when expression values changed by 2-fold.
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(B) 100 nm vs. 5 nm
Genes Fold Change
activity-regulated cytoskeleton-associated protein 48.0 
heat shock 70kDa protein 7 (HSP70B) 28.9 
heme oxygenase (decycling) 1 12.6 
interleukin 8 11.5 
heat shock 70kDa protein 6 (HSP70B') 9.9 
metallothionein 1G 6.0 
interleukin 11 6.0 
metallothionein 1B 5.4 
interleukin 1 receptor-like 1 5.4 
metallothionein 1E 4.7 
heat shock 70kDa protein 1-like 4.5 
heat shock 70kDa protein 1B 4.4 
metallothionein 1M 3.8 
heat shock 70kDa protein 9 (mortalin) 3.7 
BCL2-associated athanogene 3 3.6 
heat shock 70kDa protein 1A 3.4 
VGF nerve growth factor inducible 3.1 
BCL2-related protein A1 2.4 
interleukin 6 receptor 2.2 
heat shock 22kDa protein 8 2.1 
Notes: Significant transcripts were selected when expression values changed by 2-fold.
７９
Table 22. List of changed interleukin receptor genes after silver NPs exposure
Genes Fold change Gene description
IL1R1 1.2 interleukin 1 receptor, type I 
IL1R2 1.0 interleukin 1 receptor, type II 
IL1RL1 5.4 interleukin 1 receptor-like 1 
IL1RL2 1.0 interleukin 1 receptor-like 2 
IL2RA 1.0 interleukin 2 receptor, alpha 
IL2RB 1.0 interleukin 2 receptor, beta 
IL2RG 1.0 interleukin 2 receptor, gamma 
IL3RA 1.0 interleukin 3 receptor, alpha (low affinity) 
IL4R 1.9 interleukin 4 receptor 
IL5RA 1.0 interleukin 5 receptor, alpha 
IL6R 2.2 interleukin 6 receptor 
IL7R 1.0 interleukin 7 receptor 
CXCR1 1.1
chemokine (C-X-C motif) receptor 1 
(interleukin-8 receptor activity)
IL9R 1.0 interleukin 9 receptor 
IL10RA 1.6 interleukin 10 receptor, alpha 
IL10RB -1.4 interleukin 10 receptor, beta 
IL11RA -1.2 interleukin 11 receptor, alpha 
IL12RB1 1.0 interleukin 12 receptor, beta 1 
IL12RB2 1.0 interleukin 12 receptor, beta 2 
IL13RA1 1.0 interleukin 13 receptor, alpha 1 
IL13RA2 1.2 interleukin 13 receptor, alpha 2 
IL15RA 1.0 interleukin 15 receptor, alpha 
IL18R1 1.0 interleukin 18 receptor 1 
IL20RA 1.0 interleukin 20 receptor, alpha 
IL20RB 1.0 interleukin 20 receptor beta 
IL21R 1.0 interleukin 21 receptor 
IL22RA1 -1.1 interleukin 22 receptor, alpha 1 
IL22RA2 1.0 interleukin 22 receptor, alpha 2 
IL23R 1.0 interleukin 23 receptor 
IL27RA 1.0 interleukin 27 receptor, alpha 
Notes : control vs. 5 nm
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Figure 12. Hierarchical clustering. Heat map of genes showing microarray-
based differential expression in BEAS-2B cells. Genes were filtered for 
absolute fold change > 2. Red indicates high expression and green indicates 
low expression. (A) Control vs. cells treated with 5 nm NPs. (B) Cells 
treated with 100 nm NPs vs. cells treated with 5 nm NPs. 
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3.3.3. Classification of genes that showed increased expression following 
treatment with silver NPs
Next, we classified the genes that showed an absolute fold change of 2.0 
or greater, based on the microarray analysis of cells treated with 5 nm 
silver NPs and 100 nm silver NPs. Genes were divided into five categories 
based on gene ontology term: cell death (Table 23), cell survival (Table 
25), inflammation (Table 28), apoptosis (Table 31), and ROS (Table 34). 
The cell death category includes genes involved in regulation of cell death. 
The number of genes regulating cell death was 49. HO-1 and HSP70 are 
included herein. As shown in Table 24, HMOX1 and HSPA1B showed 18.1-
fold and 4.2-fold changes in expression, respectively, which were 
significantly higher than the control. The cell survival category includes 
genes involved in regulation of cell proliferation and regulation of epithelial 
cell proliferation. The number of genes regulating cell proliferation was 31. 
HO-1, IL-8 and IL-11 are included herein. As shown in Table 26, HMOX1, 
IL8 and IL11 showed 18.1-fold, 9.8-fold and 6.2-fold changes in 
expression, respectively, which were significantly higher than the control. 
Also the number of genes regulating epithelial cell proliferation was 3 
(Table 27). The inflammation category included inflammatory response and 
genes involved in cytokines and inflammatory response. The number of 
genes inflammatory response was 16. HO-1 and IL-8 are included herein 
(Table 29). In addition, the number of genes cytokines and inflammatory 
response was 3. IL-8 and IL-11 are included herein (Table 30). The 
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apoptosis category included regulation of apoptosis and apoptotic 
mitochondrial changes. The number of genes regulation of apoptosis was 
49. HO-1 and HSP70 are included herein (Table 32). The number genes 
apoptotic mitochondrial changes was 3 (Table 33). Lastly, the ROS-related 
category includes genes involved in response to oxidative stress and ion 
binding. The number of genes response to oxidative stress was 11. HO-1 
was included herein (Table 35). The number of genes ion binding was 74. 
As shown in Table 36, HMOX1 and MT1 showed 18.1-fold and 12.8-fold 
changes in expression, respectively, which were significantly higher than 
the control. The high fold change of MT1 is to be due to the silver NP 
belongs to the metal.
In particular, IL-11 was included in the cell survival and inflammation 
categories. These results suggest that exposure to the 5 nm silver NPs 
activated genes involved in inflammation and ROS, as well as those involved 
in cell proliferation. Most of the stress-related genes were included in the 
cell death, apoptosis, and ROS categories. 
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Table 23. Classification of increased genes associated with cell death 
categories
Ontology term Count
regulation of cell death 49
regulation of programmed cell death 49
negative regulation of programmed cell death 36
negative regulation of cell death 36
death 28
cell death 27
programmed cell death 26
positive regulation of cell death 17
positive regulation of programmed cell death 17
induction of programmed cell death 11
Notes: Significant transcripts were selected when expression values changed by 2-fold.
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Table 24. Regulation of cell death genes
Fold 
Change
Gene 
Symbol
Gene Description
18.1 HMOX1 heme oxygenase (decycling) 1 
10.6 NR4A1 "nuclear receptor subfamily 4, group A, member 1 "
9.7 DDIT3 DNA-damage-inducible transcript 3 
4.9 SERPINB2 "serpin peptidase inhibitor, clade B (ovalbumin), member 2 "
4.5 KLF10 Kruppel-like factor 10 
4.5 PMAIP1 phorbol-12-myristate-13-acetate-induced protein 1 
4.4 DUSP1 dual specificity phosphatase 1 
4.2 HSPA1B heat shock 70kDa protein 1B 
4.1 PIM1 pim-1 oncogene 
4.0 HSPA1B heat shock 70kDa protein 1B 
4.0 HSPA1B heat shock 70kDa protein 1B 
3.9 DDIT3 DNA-damage-inducible transcript 3 
3.7 UBC ubiquitin C 
3.7 BAG3 BCL2-associated athanogene 3 
3.7 HSPA1B heat shock 70kDa protein 1B 
3.6 CRYAB "crystallin, alpha B "
3.5 HSPA1B heat shock 70kDa protein 1B // heat shock 70kDa protein 1A 
3.5 HSPA1A heat shock 70kDa protein 1A 
3.4 ROCK1P1 "Rho-associated, coiled-coil containing protein kinase 1 
pseudogene 1 "
3.4 HSPA9 heat shock 70kDa protein 9 (mortalin) 
3.2 ANGPTL4 angiopoietin-like 4 
3.2 JUN jun proto-oncogene 
3.2 HSPA1A heat shock 70kDa protein 1A 
3.2 ERN1 endoplasmic reticulum to nucleus signaling 1 
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3.1 HSPA1A heat shock 70kDa protein 1A 
3.1 HSPA1A heat shock 70kDa protein 1A 
3.1 HSPA1A heat shock 70kDa protein 1A 
3.1 HRK "harakiri, BCL2 interacting protein (contains only BH3 domain) "
3.0 NR4A2 "nuclear receptor subfamily 4, group A, member 2 "
3.0 TNFAIP3 "tumor necrosis factor, alpha-induced protein 3 "
3.0 VEGFA vascular endothelial growth factor A 
2.9 CEBPB "CCAAT/enhancer binding protein (C/EBP), beta "
2.8 DEDD2 death effector domain containing 2 
2.7 DNAJB6 "DnaJ (Hsp40) homolog, subfamily B, member 6 "
2.7 TNFRSF10D "tumor necrosis factor receptor superfamily, member 10d, decoy with truncated death domain "
2.6 SOX9 SRY (sex determining region Y)-box 9 
2.5 SOCS3 suppressor of cytokine signaling 3 
2.4 TGM2 "transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase) "
2.4 TBX3 T-box 3 
2.4 CLU clusterin 
2.2 FOSL1 FOS-like antigen 1 
2.2 IL6R interleukin 6 receptor 
2.2 NOTCH1 notch 1 
2.1 GCLM "glutamate-cysteine ligase, modifier subunit "
2.1 CLCF1 cardiotrophin-like cytokine factor 1 
2.1 SPHK1 sphingosine kinase 1 
2.1 IER3 immediate early response 3 
2.1 UBB ubiquitin B 
2.0 CSF2 colony stimulating factor 2 (granulocyte-macrophage) 
Notes: Significant transcripts were selected when expression values changed by 2-fold.
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Table 25. Classification of increased genes associated with cell survival 
categories
Ontology term Count
regulation of survival gene product expression 2
B Cell Survival Pathway 2
regulation of cell proliferation 31
positive regulation of cell proliferation 20
cell proliferation 16
negative regulation of cell proliferation 12
regulation of smooth muscle cell proliferation 7
positive regulation of smooth muscle cell proliferation 5
regulation of epithelial cell proliferation 3
positive regulation of epithelial cell proliferation 2
Cadmium induces DNA synthesis and proliferation in macrophages 2
Inhibition of Cellular Proliferation by Gleevec 2
Notes: Significant transcripts were selected when expression values changed by 2-fold.
８７
Table 26. Regulation of cell proliferation
Fold 
Change
Gene 
Symbol
Gene Description
18.1 HMOX1 heme oxygenase (decycling) 1 
9.8 IL8 interleukin 8 
7.8 DDR2 discoidin domain receptor tyrosine kinase 2 
7.5 TRIB1 tribbles homolog 1 (Drosophila) 
6.9 XIRP1 xin actin-binding repeat containing 1 
6.5 NPPC natriuretic peptide C 
6.2 IL11 interleukin 11 
5.4 ADAMTS1 "ADAM metallopeptidase with thrombospondin type 1 motif, 1 "
4.5 KLF10 Kruppel-like factor 10 
4.5 FABP3
"fatty acid binding protein 3, muscle and heart (mammary-derived 
growth inhibitor) "
4.0 LIF leukemia inhibitory factor 
3.2 JUN jun proto-oncogene 
3.1 PTHLH parathyroid hormone-like hormone 
3.1 MMP12 matrix metallopeptidase 12 (macrophage elastase) 
3.1 EGR4 early growth response 4 
3.0 VEGFA vascular endothelial growth factor A 
2.8 ATF3 activating transcription factor 3 
2.8 SERTAD1 SERTA domain containing 1 
2.7 FGF18 fibroblast growth factor 18 
2.6 HBEGF heparin-binding EGF-like growth factor 
2.6 SOX9 SRY (sex determining region Y)-box 9 
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2.4 TGM2
"transglutaminase 2 (C polypeptide, protein-glutamine-gamma-
glutamyltransferase) "
2.4 TBX3 T-box 3 
2.4 CLU clusterin 
2.2 FOSL1 FOS-like antigen 1 
2.2 JAG1 jagged 1 
2.2 IL6R interleukin 6 receptor 
2.2 NOTCH1 notch 1 
2.1 CXCL1
"chemokine (C-X-C motif) ligand 1 (melanoma growth 
stimulating activity, alpha) "
2.1 SPHK1 sphingosine kinase 1 
2.0 CSF2 colony stimulating factor 2 (granulocyte-macrophage) 
Notes: Significant transcripts were selected when expression values changed by 2-fold.
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Table 27. Regulation of epithelial cell proliferation
Fold 
Change
Gene Symbol Gene Description
3.1 MMP12 matrix metallopeptidase 12 (macrophage elastase) 
3.0 VEGFA vascular endothelial growth factor A 
2.2 NOTCH1 notch 1 
Notes: Significant transcripts were selected when expression values changed by 2-fold.
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Table 28. Classification of increased genes associated with inflammation 
categories
Ontology term Count
inflammatory response 16
acute inflammatory response 3
Cytokines and Inflammatory Response 3
Cells and Molecules involved in local acute inflammatory response 3
Notes: Significant transcripts were selected when expression values changed by 2-fold.
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Table 29. Inflammatory response
Fold 
Change
Gene 
Symbol
Gene Description
18.1 HMOX1 heme oxygenase (decycling) 1 
9.8 IL8 interleukin 8 
8.3 KDM6B lysine (K)-specific demethylase 6B 
4.0 FOS
FBJ murine osteosarcoma viral oncogene homolog 
3.4 CYP4F11 "cytochrome P450, family 4, subfamily F, polypeptide 11 "
3.0 MMP25 matrix metallopeptidase 25 
2.9 CEBPB
"CCAAT/enhancer binding protein (C/EBP), beta "
2.5 CCL26 chemokine (C-C motif) ligand 26 
2.4 CLU clusterin 
2.3 HRH1 histamine receptor H1 
2.2 IL6R interleukin 6 receptor 
2.1 PTAFR platelet-activating factor receptor 
2.1 CXCL1
"chemokine (C-X-C motif) ligand 1 (melanoma growth 
stimulating activity, alpha) "
2.1 MAP2K3 mitogen-activated protein kinase kinase 3 
2.0 IRGM "immunity-related GTPase family, M "
2.0 ITGAL
"integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated 
antigen 1; alpha polypeptide) "
Notes: Significant transcripts were selected when expression values changed by 2-fold.
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Table 30. Cytokines and Inflammatory Response
Fold 
Change
Gene 
Symbol
Gene Description
9.8 IL8 interleukin 8 
6.2 IL11 interleukin 11 
2.0 CSF2 colony stimulating factor 2 (granulocyte-macrophage) 
Notes: Significant transcripts were selected when expression values changed by 2-fold.
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Table 31. Classification of increased genes associated with apoptosis 
categories
Ontology term Count
regulation of apoptosis 49
negative regulation of apoptosis 36
anti-apoptosis 29
apoptosis 25
positive regulation of apoptosis 17
induction of apoptosis 11
regulation of neuron apoptosis 5
regulation of anti-apoptosis 5
positive regulation of anti-apoptosis 4
induction of apoptosis by extracellular signals 3
positive regulation of neuron apoptosis 2
PTEN dependent cell cycle arrest and apoptosis 1
TSP-1 Induced Apoptosis in Microvascular Endothelial Cell 2
Neuropeptides VIP and PACAP inhibit the apoptosis of activated T cells 2
apoptotic mitochondrial changes 3
Notes: Significant transcripts were selected when expression values changed by 2-fold.
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Table 32. Regulation of apoptosis
Fold 
Change
Gene 
Symbol
Gene Description
18.1 HMOX1 heme oxygenase (decycling) 1 
10.6 NR4A1 "nuclear receptor subfamily 4, group A, member 1 "
9.7 DDIT3 DNA-damage-inducible transcript 3 
4.9 SERPINB2 "serpin peptidase inhibitor, clade B (ovalbumin), member 2 "
4.5 KLF10 Kruppel-like factor 10 
4.5 PMAIP1 phorbol-12-myristate-13-acetate-induced protein 1 
4.4 DUSP1 dual specificity phosphatase 1 
4.2 HSPA1B heat shock 70kDa protein 1B 
4.1 PIM1 pim-1 oncogene 
4.0 HSPA1B heat shock 70kDa protein 1B 
4.0 HSPA1B heat shock 70kDa protein 1B 
3.9 DDIT3 DNA-damage-inducible transcript 3 
3.7 UBC ubiquitin C 
3.7 BAG3 BCL2-associated athanogene 3 
3.7 HSPA1B heat shock 70kDa protein 1B 
3.6 CRYAB "crystallin, alpha B "
3.5 HSPA1B heat shock 70kDa protein 1B // heat shock 70kDa protein 1A 
3.5 HSPA1A heat shock 70kDa protein 1A 
3.4 ROCK1P1 "Rho-associated, coiled-coil containing protein kinase 1 pseudogene 1 "
3.4 HSPA9 heat shock 70kDa protein 9 (mortalin) 
3.2 ANGPTL4 angiopoietin-like 4 
3.2 JUN jun proto-oncogene 
3.2 HSPA1A heat shock 70kDa protein 1A 
3.2 ERN1 endoplasmic reticulum to nucleus signaling 1 
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3.1 HSPA1A heat shock 70kDa protein 1A 
3.1 HSPA1A heat shock 70kDa protein 1A 
3.1 HSPA1A heat shock 70kDa protein 1A 
3.1 HRK "harakiri, BCL2 interacting protein (contains only BH3 domain) "
3.0 NR4A2 "nuclear receptor subfamily 4, group A, member 2 "
3.0 TNFAIP3 "tumor necrosis factor, alpha-induced protein 3 "
3.0 VEGFA vascular endothelial growth factor A 
2.9 CEBPB "CCAAT/enhancer binding protein (C/EBP), beta "
2.8 DEDD2 death effector domain containing 2 
2.7 DNAJB6 "DnaJ (Hsp40) homolog, subfamily B, member 6 "
2.7 TNFRSF10D "tumor necrosis factor receptor superfamily, member 10d, decoy with truncated death domain "
2.6 SOX9 SRY (sex determining region Y)-box 9 
2.5 SOCS3 suppressor of cytokine signaling 3 
2.4 TGM2 "transglutaminase 2 (C polypeptide, protein-glutamine-gamma-
glutamyltransferase) "
2.4 TBX3 T-box 3 
2.4 CLU clusterin 
2.2 FOSL1 FOS-like antigen 1 
2.2 IL6R interleukin 6 receptor 
2.2 NOTCH1 notch 1 
2.1 GCLM "glutamate-cysteine ligase, modifier subunit "
2.1 CLCF1 cardiotrophin-like cytokine factor 1 
2.1 SPHK1 sphingosine kinase 1 
2.1 IER3 immediate early response 3 
2.1 UBB ubiquitin B 
2.0 CSF2 colony stimulating factor 2 (granulocyte-macrophage) 
Notes: Significant transcripts were selected when expression values changed by 2-fold.
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Table 33. Apoptotic mitochondrial changes
Fold Change Gene Symbol Gene Description
4.5 PMAIP1 phorbol-12-myristate-13-acetate-induced protein 1 
3.2 JUN jun proto-oncogene 
2.4 CLU clusterin 
Notes: Significant transcripts were selected when expression values changed by 2-fold.
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Table 34. Classification of increased genes associated with ROS categories
Ontology term Count
response to reactive oxygen species 8
response to oxidative stress 11
Oxidative Stress Induced Gene Expression Via Nrf2 3
cellular response to oxidative stress 2
ion binding 74
magnesium ion binding 10
metal ion binding 74
transition metal ion binding 58
zinc ion binding 49
calcium ion binding 14
iron ion binding 7
copper ion binding 6
cadmium ion binding 6
manganese ion binding 3
Notes: Significant transcripts were selected when expression values changed by 2-fold.
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Table 35. Response to oxidative stress
Fold Change Gene Symbol Gene Description
18.1 HMOX1 heme oxygenase (decycling) 1 
9.7 DDIT3 DNA-damage-inducible transcript 3 
4.4 DUSP1 dual specificity phosphatase 1 
4.0 FOS
FBJ murine osteosarcoma viral oncogene homolog 
3.9 DDIT3 DNA-damage-inducible transcript 3 
3.6 CRYAB "crystallin, alpha B "
3.2 JUN jun proto-oncogene 
3.0 SRXN1 sulfiredoxin 1 
2.4 CLU clusterin 
2.2 FOSL1 FOS-like antigen 1 
2.1 GCLM "glutamate-cysteine ligase, modifier subunit "
Notes: Significant transcripts were selected when expression values changed by 2-fold.
９９
Table 36. Ion binding
Fold 
Change
Gene 
Symbol
Gene Description
25.7 DNAJA4 "DnaJ (Hsp40) homolog, subfamily A, member 4 "
22.7 MMP10 matrix metallopeptidase 10 (stromelysin 2) 
18.5 DLL1 delta-like 1 (Drosophila) 
18.1 HMOX1 heme oxygenase (decycling) 1 
16.2 SNAI1 snail family zinc finger 1 
12.8 MT1B metallothionein 1B 
12.7 MT1E metallothionein 1E 
10.6 NR4A1 "nuclear receptor subfamily 4, group A, member 1 "
10.3 MMP3 "matrix metallopeptidase 3 (stromelysin 1, progelatinase) "
9.7 SLC30A1 "solute carrier family 30 (zinc transporter), member 1 "
8.9 GEM GTP binding protein overexpressed in skeletal muscle 
8.7 ZFAND2A "zinc finger, AN1-type domain 2A "
8.3 KDM6B lysine (K)-specific demethylase 6B 
6.8 MT1G metallothionein 1G 
5.4 ADAMTS1 "ADAM metallopeptidase with thrombospondin type 1 motif, 1 "
5.1 CHORDC1 cysteine and histidine-rich domain (CHORD) containing 1 
5.1 MT1M metallothionein 1M 
5.1 ASTL astacin-like metallo-endopeptidase (M12 family) 
4.7 SIK1 salt-inducible kinase 1 
4.7 CDH16 "cadherin 16, KSP-cadherin "
4.5 KLF10 Kruppel-like factor 10 
4.1 PIM1 pim-1 oncogene 
4.1 IDI2 isopentenyl-diphosphate delta isomerase 2 
3.9 GCM1 glial cells missing homolog 1 (Drosophila) 
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3.8 NR4A3 "nuclear receptor subfamily 4, group A, member 3 "
3.7 UBC ubiquitin C 
3.6 RYBP RING1 and YY1 binding protein 
3.5 ZBTB2 zinc finger and BTB domain containing 2 
3.4 CYP4F11 "cytochrome P450, family 4, subfamily F, polypeptide 11 "
3.4 ROCK1P1 "Rho-associated, coiled-coil containing protein kinase 1 pseudogene 1 "
3.3 JHDM1D jumonji C domain containing histone demethylase 1 homolog D (S. 
cerevisiae) 
3.2 EGR3 early growth response 3 
3.2 ERN1 endoplasmic reticulum to nucleus signaling 1 
3.2 ZC3H12A zinc finger CCCH-type containing 12A 
3.1 PTHLH parathyroid hormone-like hormone 
3.1 MMP1 matrix metallopeptidase 1 (interstitial collagenase) 
3.1 MMP12 matrix metallopeptidase 12 (macrophage elastase) 
3.1 MT1F metallothionein 1F 
3.1 EGR4 early growth response 4 
3.0 NR4A2 "nuclear receptor subfamily 4, group A, member 2 "
3.0 TNFAIP3 "tumor necrosis factor, alpha-induced protein 3 "
3.0 TES testis derived transcript (3 LIM domains) 
3.0 MMP25 matrix metallopeptidase 25 
3.0 SRXN1 sulfiredoxin 1 
2.9 ZNF34 zinc finger protein 34 
2.9 ZSWIM6 "zinc finger, SWIM-type containing 6 "
2.9 ABL2 v-abl Abelson murine leukemia viral oncogene homolog 2 
2.8 TET3 tet methylcytosine dioxygenase 3 
2.7 EDEM2 "ER degradation enhancer, mannosidase alpha-like 2 "
2.7 NQO2 "NAD(P)H dehydrogenase, quinone 2 "
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2.5 SCUBE2 "signal peptide, CUB domain, EGF-like 2 "
2.4 RLF rearranged L-myc fusion 
2.4 TGM2 "transglutaminase 2 (C polypeptide, protein-glutamine-gamma-
glutamyltransferase) "
2.3 ALOXE3 arachidonate lipoxygenase 3 
2.3 ACSL5 acyl-CoA synthetase long-chain family member 5 
2.3 MT1X metallothionein 1X 
2.3 B3GNT2 "UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 "
2.2 RARA "retinoic acid receptor, alpha "
2.2 JAG1 jagged 1 
2.2 ZNF274 zinc finger protein 274 
2.2 NOTCH1 notch 1 
2.2 ZCCHC6 "zinc finger, CCHC domain containing 6 "
2.2 CARS cysteinyl-tRNA synthetase 
2.2 PHF13 PHD finger protein 13 
2.2 TIPARP TCDD-inducible poly(ADP-ribose) polymerase 
2.1 HIC1 hypermethylated in cancer 1 
2.1 JMJD1C jumonji domain containing 1C 
2.1 ZNF469 zinc finger protein 469 
2.1 SPHK1 sphingosine kinase 1 
2.1 UBB ubiquitin B 
2.0 KLF6 Kruppel-like factor 6 
2.0 CYP2B7P1 "cytochrome P450, family 2, subfamily B, polypeptide 7 pseudogene 1 "
2.0 HIVEP1 human immunodeficiency virus type I enhancer binding 
protein 1 
2.0 ITGAL "integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide) "
Notes: Significant transcripts were selected when expression values changed by 2-fold.
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3.3.4. Effects of silver NPs on cytokine production and inflammatory 
response
Cytokine production in BEAS-2B cells treated with 5 nm and 100 nm
silver NPs was assessed by ELISA. Epithelial cells were treated with 
different concentrations of silver NPs for 8 h (Figure 13A) and 24 h 
(Figure 13B). Because IL-8 is an earlier-responding cytokine, the two 
experiments used different treatment times. Supernatants harvested from 
control and cells treated with silver NPs were assayed for IL-8 and IL-11. 
IL-8 production was highest in the 0.5 ㎍/mL treatment, at 1,413 pg/mL; 
at higher concentrations of silver NPs, cell death was induced. IL-11 
production was highest in the 0.75 ㎍/mL treatment, at 3,733 pg/mL. As 
predicted, treatment with 100 nm silver NPs did not increase IL-8 and IL-
11 release. These results suggest that expression of cytokines in response 
to silver NPs is size- and dose-dependent in epithelial cells. Furthermore, 
these results support the results of the cDNA microarray analysis.
１０３
Figure 13. Dose-dependent expression of cytokines in response to silver 
NPs. (A) BEAS-2B cells treated with different doses of silver NPs for 8 h. 
(B) BEAS-2B cells treated with different doses of silver NPs for 24 h. 
Culture supernatant was harvested and levels of IL-8 and IL-11 were 
measured by ELISA. Treatment with 5 nm silver NPs induced IL-8 release, 
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but treatment with 100 nm silver NPs did not. Data represent the mean ±
SD of three independent experiments. One-way and two-way ANOVA 
analyses were used to determine significance (**p < 0.01, ***p < 0.001).
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3.3.5. Expression of genes related to cytokine production and ROS 
Real-time RT-PCR analysis was performed for IL-8, which was found to 
be significantly increased in the cDNA microarray analysis, and for IL-11, 
HSP70, and HO-1. Real-time RT-PCR analysis was performed for 6 h 
with 0.25 to 0.75 ㎍/mL of silver NPs. At concentrations ranging from 0.25 
to 0.75 ㎍/mL, IL-8 gene expression increased by 2.8-, 20.6-, and 21.6-
fold, respectively. At the same concentrations, IL-11 gene expression 
increased by 1.3-, 11.5-, and 15.6-fold, respectively (Figure 14A). In 
addition, at the same doses, HSP70 gene expression increased by 16-, 
85.6-, and 103.2-fold, respectively. Lastly, at these concentrations, HO-1 
gene expression increased by 54.9-, 243.5-, and 163-fold, respectively 
(Figure 14B). In concordance with the microarray data, expression of 
genes related to cytokine production and ROS increased after treatment 
with 5 nm silver NPs. However, 100 nm silver NPs did not increase the 
expression of IL-8, IL-11, HSP70, or HO-1. These results indicate that 
the results of the microarray and real-time RT-PCR analyses are 
concordant. 
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Figure 14. Expression of genes related to cytokine production and ROS in
bronchial epithelial cells treated with silver NPs. (A) Real-time RT-PCR 
analysis was performed for 6 h at 0.25 ㎍/mL to 0.75 ㎍/mL of silver NPs. 
Expression of genes related to cytokine production increased after 
treatment with 5 nm silver NPs, but not after treatment with 100 nm silver 
NPs. (B) Expression of ROS-related genes. Real-time RT-PCR analysis 
was performed for 6 h at 0.25 ㎍/mL to 0.75 ㎍/mL of silver NPs. 
Exposure to 5 nm silver NPs induced increased expression of HSP70 and 
HO-1. Exposure to 100 nm silver NPs did not induce increased expression 
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of HSP70 and HO-1. Real-time RT-PCR was performed three times and 
representative data are shown. Data are shown as the mean ± SD of three 
or more independent experiments. One-way and two-way ANOVA 
analyses were used to determine significance (**p < 0.01, ***p < 0.001).
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3.3.6. Effects of silver NPs on HSP70 and HO-1 expression
Two proteins (HSP70 and HO-1) were chosen for further analysis using 
western blotting, based on increased expression in response to treatment 
with 5 nm silver NPs. In accordance with the realtime-PCR results showed 
that RNA levels of HSP70 increased to a maximum of 103.2-fold and HO-
1 increased to a maximum of 243.5-fold at 6 h-exposure. Therefore we 
tested the effect of silver NPs on the expression of HSP70 and HO-1 
protein in BEAS-2B cells. BEAS-2B cells were treated with different 
doses of silver NPs for 24 h. Each 30-㎍ protein sample was loaded and 
analyzed with anti-HSP70, anti-HO-1, and anti-GAPDH (loading control) 
antibodies. HSP70 and HO-1 expression increased in cells treated with 
high-dose silver NPs compared to untreated cells. HSP70 protein levels 
increased by a maximum of 7.7-fold at 0.5 ㎍/mL and HO-1 protein levels 
increased by a maximum of 8.9-fold at the same concentration, compared 
to untreated cells (Figure 15). In contrast, ROS-associated proteins were 
not affected by treatment with 100 nm silver NPs. These results suggest 
that exposure to silver NPs could increase the expression of proteins 
related to oxidative stress. 
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Figure 15. Protein levels of HSP70 and HO-1 in bronchial epithelial cells 
treated with silver NPs. BEAS-2B cells were treated with different doses 
of silver NPs for 24 h. Each 30-㎍ protein sample was analyzed using 
anti-HSP70, anti-HO-1, and anti-GAPDH (loading control) antibodies.
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4. Discussion
Today, engineered nanomaterials are being applied and used in various 
consumer products. In particular, the use of silver NPs has gradually 
increased due to its antimicrobial and unique physical characteristics. 
However, a growing number of studies report that silver NPs are toxic to 
the human due to the small size of its particles. Since the potential health 
impact of nanomaterials increases with the rapid growth of nano-industry, 
it is important to fully investigate the safety of and their potential hazards 
(2).
In this study, the safety of silver NPs was investigated by examining the
effect of silver NPs on endothelial and epithelial cells. Most previous 
studies anticipated that NP inhalation mainly affects the epithelial cells of 
respiratory tissues. However, studies verify that NPs introduced through
the respiratory system are found in various other organs outside of the
respiratory system (21). This means that it can penetrate through 
epithelial cells to endothelial cells due to its extremely small size. 
Endothelial cells are cells surrounding blood vessels, and nanoparticles 
penetrating into endothelial cells can affect various organs through blood 
stream. 
First, we evaluated the cytotoxic effects of silver NPs in endothelial and 
epithelial cells. Although the LD50 of each cell line was estimated 
differently, the toxicity of silver NPs was proven. However, for 100 nm 
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silver NPs, cell death was not observed in the high concentration group 
(endothelial cells: 3.5 ㎍/mL; epithelial cells: 1.5 ㎍/mL). It can therefore
be suggested that the cytotoxicity of silver NPs depends on the size of 
particles and on the treatment dose. In a prior study, we evaluated the 
effect of silver NPs in macrophage cells. It was verified through microarray 
that 5 nm silver NPs affect the variation of gene expression in cells, and a 
noticeable increase in the expression of the IL-8 gene and of oxidative-
stress related gene in early time was also verified (11). Similarly, we were 
also able to verify that the expression of not only oxidative stress-related 
genes but also inflammatory response-related genes increased in response 
to exposure to 5 nm silver NPs in both endothelial and epithelial cells. 
Oxidative stress-induced ROS is produced in cell death or early time 
before cellular damage (49). We also found variation in oxidative stress-
related genes in early after exposure, among which the variation in
metallothionein (MT), heme oxygenase 1 (HO-1), and heat shock 70kDa 
protein (HSP70) were especially noticeable. In one earlier study, 20–50 nm 
silver NPs were added to A549 cells, producing oxidative stress products 
such as malondialdehyde (MDA) and 8-hydroxy-2’-deoxyguanosine
(8-oxo-dG) and consequently increasing levels of HSP and HO-1 (50). 
This is similar to the results of our study. Our study has proven that 
HSP70, HO-1, and MT are sufficient as biomarkers of ROS and that the 
oxidative stress effect increases as NP size decreases, given that there is 
no variation in ROS related gene expression following exposure to 100 nm 
１１２
silver NPs.
The microarray used in this study can analyze up to 24,838 RefSeq 
(Entrez) genes. Based on the results of this analysis, genes undergoing 
intracellular change after exposure to silver NPs were classified into five
categories: cell death, cell survival, inflammation, apoptosis, and ROS. As a 
result, there was considerable variation in genes related to cell death and 
apoptosis, and the expression of genes related to cell survival was also 
significant. Meanwhile, the number of genes related to inflammation was 
relatively small. This is supported by our review of previous research, 
which showed that only IL-8 gene expression among cytokines increased
shortly after the exposure of macrophage cells to 5 nm silver NPs (11). 
However, this study was increased with the addition to the IL-8, IL-11, 
IL-1α and IL-36α into endothelial cells. In epithelial cells, the only
intracellular cytokines that increased following exposure to 5 nm of silver 
NPs were IL-8 and IL-11. In addition, ROS-related genes were the most 
marked as ion binding ontology terms. It might be because silver NPs are 
gradually ionized to Ag+ over time, and accordingly the variation of ion-
binding related genes developed actively. A previous study has suggests 
that toxicity is generated by free silver ions induced by silver NPs, but this 
is a combined effect of silver ions and silver NPs (51).
One point especially worth paying attention to is the increased IL-11 
gene expression, which has not been greatly discussed in previous studies. 
In this study, the expression of the IL-11 gene particularly increased 
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following exposure to 5 nm silver NPs in both endothelial cells and
epithelial cells. IL-11 increases the frequency and proportion of 
proliferating megakaryocytes in bone marrow. This role of IL-11 in bone 
marrow failure syndromes, such as aplastic anemia and myelodysplastic 
syndrome, is being investigated in clinical trials. IL-11 also stimulates 
myeloid and erythroid differentiation and regulates macrophage precursors. 
Its potential in treating mild hemophilia A is suggested. As an anti-
inflammatory cytokine, IL-11 has been identified as having 
immunomodulatory activities by reducing pro-inflammatory cytokine 
synthesis. Based on the pivotal role of IL-11 in inflammatory conditions, it 
has been investigated as a candidate for treating rheumatoid arthritis, 
Crohn’s disease, refractory immune thrombocytopenic purpura, and 
periodontal disease (52). Thus IL-11 has various functions, and it roles 
can vary by cell type (48). One study suggests that IL-11 is involved in 
cell proliferation in endothelial cells. The study indicates that IL-11 is 
related to the STAT3 pathway, and accordingly surviving proteins are
expressed and have a positive effect on cell proliferation (53). However, 
considering that this study’s microarray results showed increased 
expression of 31 genes including IL-11 in epithelial cells as well as 20 
genes including IL-11 in endothelial cells, which were classified as 
ontology term as regulation of cell proliferation, it was inferred that IL-11 
plays a role in cell proliferation not only in endothelial cells but also in 
epithelial cells. Moreover, IL-11 is classified as an anti-inflammatory 
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cytokine, and the microarray results for endothelial cells showed a 10.4-
fold increase in its expression, which was much higher than other cytokines. 
This also might have affected the proliferation of endothelial cells. In 
addition, genes whose ontology terms classify them as regulating apoptosis
showed an increased expression of 37 in endothelial cells and 49 in 
epithelial cells. Although IL-11 is associated with apoptosis and thus 
induces cell death in both endothelial and epithelial cells, it stimulates more 
genes in epithelial cells. This is supported by earlier studies, that argued
that one of the various functions of IL-11 is induction of apoptosis in 
epithelial cells (54, 55, 56). Given the great variety of roles played by IL-
11, it is difficult to determine its role in a specific cell. Therefore, although 
this study has verified that IL-11 expression commonly increases in cells 
due to the influence of silver NPs, additional studies using various methods 
will be required in the future, as the specific roles played by IL-11 can 
vary by cell type.
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5. Conclusions
A summary of this study’s results is as follows:
1. Endothelial and epithelial cell viability was dependent on silver NP
particle size. Cell death was induced by 5 nm silver NPs. The viability of 
cells treated with 5 nm and 100 nm silver NPs differed. 
2. The number of genes whose expression increased due to silver NPs was 
much higher in the 5 nm treatment group than in the 100 nm group. This 
also proves that smaller NPs have stronger toxicity.
3. The genes that increased greatly following exposure to silver NPs were
mainly oxidative stress effect-related genes such as MT, HO-1, and 
HSP70, and this is related to the induction of cellular toxicity by silver 
NPs following the ROS pathway.
4. The cytokines increased by exposure to silver NPs were IL-8 and IL-
11. The expression of these cytokines increased even early following 
exposure, which does not have high cellular toxicity. It can be assumed 
that early after exposure the inflammatory response action and the anti-
inflammatory response act at the same time.
5. IL-11 has exhibits many different functions, and, its roles appear to
vary by cell types. IL-11 can induce apoptosis by exacerbating
inflammation and can also regulate cell proliferation.
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6. Silver NPs create a toxic effect response in both endothelial and 
epithelial cells. They also stimulate genes involved in cell activities such 
as cell death, cell survival, inflammation, apoptosis, and oxidative stress.
7. After treatment with 5 nm silver NPs, mitochondrial swelling, a decrease 
or disappearance of cytoplasm, and vacuolization were observed. But
after treatment with 100 nm silver NPs, no clear changes in cell 
morphology were observed except for the presence of NPs in lysosomes 
and the nucleus. 
In conclusion, this study finds that intracellular genes specifically respond 
to exposure to silver NPs, and among cytokines the expression of IL-11 is 
especially significant. It also finds that toxic effect is affected by the size of 
NPs. However, this study only verifies that IL-11 expression increased; 
further study will be required to in order to elucidate the various roles 
played by IL-11. 
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ABSTRACT (in KOREAN)
사람 내피세포와 기관지 상피세포에서
은 나노입자에 의한 인터루킨 11 과 스트레스 유전자의 증가
장 지 영
연세대학교 대학원 나노메디컬협동과정
(지도교수 최 인 홍)
초미립자 나노물질의 크기는 약 100 nm 정도로 이러한 작은 크기의 특성으로
인하여 산업적으로 여러 방면에서 활용이 되고 있다. 그 중 은 나노입자는
항균작용의 영향으로 의학분야에서 많이 활용되고 있다. 그러나 최근들어 은
나노입자가 인체에 유해한 영향을 미치는 원인물질로 지목되면서 많은
연구자들이 은 나노입자 뿐만 아니라 전반적인 나노입자에 대한 독성 평가와
위해성 평가를 진행하고 있다. 
본 연구에서는 은 나노입자를 사람 내피세포와 상피세포로 구분하여 일정시간
노출시킨 후 관찰되는 여러가지 세포 반응들을 확인하고자 하였다. 은
１２７
나노입자에 의해 세포내 산화적 스트레스가 발생하여 세포사멸이 진행되고
어떠한 유전자들이 자극을 받아 변화가 관찰되는지 확인해 보고자 하였다. 
그리고 나노입자에 노출 된 후 세포 내 여러 유전자들의 발현 양상의 변화를
마이크로어레이 기법을 통하여 확인하였다. 
연구 결과, 사람 내피세포와 상피세포 에서 반치사농도 값은 각각 다르게
산출되었지만 공통적으로 5 nm 은 나노입자에 대한 세포독성이 확인되었다. 
나노입자처럼 크기가 작은 물질은 세포내부로 침투하여 사멸을 유도하는데 5 
nm 은 나노입자는 세포 내부로 침투하여 세포질을 파괴하는 것을 확인하였지만
100 nm 은 나노입자는 세포내부로 일부의 입자가 침투되기는 하나 세포 손상을
일으키지는 않았다. 은 나노입자의 노출로 인하여 세포 내에서 발현이 증가하는
유전자의 개수는 100 nm 보다 5 nm 에서 월등히 많이 확인되었다. 은
나노입자에 의하여 증가 발현의 폭이 큰 유전자들은 대표적으로 메탈로티오닌
(MT, metallothionein), 헴 옥시게나아제 1 (HO-1, heme oxygenasae 1), 열
충격 단백질 70 (HSP70, heat shock 70kDa protein)과 같이 주로 산화적
스트레스와 관련된 유전자이며 이는 은 나노입자가 주로 활성산소 기전을 따라
세포독성이 유도되는 것과 연관된다. 그리고 은 나노입자에 의해 증가되는 주된
사이토카인은 인터루킨 8 과 11 이었으며 세포독성이 크지 않은 노출초기에도
이들 사이토카인의 발현이 증가되었다. 이는 노출 초기에도 염증반응이
작용하며 동시에 항염증반응 또한 작용함을 추측할 수 있었다. 이와 같이 은
나노입자는 사람 내피세포와 상피세포 모두에서 독성 반응을 유발하였으며
세포사멸, 세포증식, 염증반응, 산화적 스트레스 등 세포활성에 관여하는
전반적인 유전자들을 자극시켰다. 
１２８
결론적으로, 본 연구에서는 은 나노입자가 세포에 노출되면 세포내 유전자들이
특이적으로 반응을 한다는 것과 사이토카인들 중에서 특별히 인터루킨 11 의
발현이 두드러짐을 발견하였다. 그리고 세포에 대한 독성 영향은 나노입자의
크기와 깊은 연관이 있음을 재확인하였다. 하지만 이번 연구에서는 은
나노입자에 의하여 인터루킨 11 이 증가 발현이 되었다는 현상만 확인되었을
뿐이므로 향후 추가적으로 인터루킨 11 의 다양한 역할을 입증할 수 있도록
여러 방면에서 추가연구가 진행되어야 할 것이다. 
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